\Program Files\Common Files\System\Mapi\1033\NT





ain nodes :
6 8 9 10 11 15
ng nodes :
1 2 3 4 5
ain bonds :
4-8 5-6 8-9 9-15
ng bonds :
1-2 1-5 2-3 3-4 4-5
tact/norm bonds :
1-2 1-5 2-3 3-4 4-5 5-6 9-15
tact bonds :
4-8 8-9
olated ring systems :
containing 1 :

:[*1],[*2]

tch level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:CLASS 8:CLASS 9:CLASS 10:Atom 11:Atom
15:CLASS
eneric attributes :
11:
Saturation : Unsaturated

\Program Files\Common Files\System\Mapi\1033\NT





ain nodes :
6 8
ng nodes :
1 2 3 4 5
ain bonds :
5-6 6-8
ng bonds :
1-2 1-5 2-3 3-4 4-5
act/norm bonds :
1-2 1-5 2-3 3-4 4-5 5-6 6-8
olated ring systems :
containing 1 :

tch level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:CLASS 8:CLASS

\Program Files\Common Files\System\Mapi\1033\NT






```
ain nodes :
   6  8  9
ing nodes :
   1  2  3  4  5
ing/chain nodes :
   10
ain bonds :
   1-10  4-8  5-6  8-9
ing bonds :
   1-2  1-5  2-3  3-4  4-5
xact/norm bonds :
   1-2  1-5  1-10  2-3  3-4  4-5  5-6
xact bonds :
   4-8  8-9
solated ring systems :
   containing 1 :


atch level :
   1:Atom  2:Atom  3:Atom  4:Atom  5:Atom  6:CLASS  8:CLASS  9:CLASS  10:CLASS
```

=>
Uploading C:\Program Files\Common Files\System\Mapi\1033\NT\10009607 (amended).str
Cb *2 11 *2

Hy *1 10 *1





chain nodes :
6 8 9 10 11 15
ring nodes :
1 2 3 4 5
chain bonds :
4-8 5-6 8-9 9-15
ring bonds :
1-2 1-5 2-3 3-4 4-5
exact/norm bonds :
1-2 1-5 2-3 3-4 4-5 5-6 9-15
exact bonds :
4-8 8-9
isolated ring systems :
containing 1 :

G1:[*1],[*2]

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:CLASS 8:CLASS 9:CLASS 10:Atom 11:Atom
15:CLASS
Generic attributes :
11:
Saturation : Unsaturated

L1 STRUCTURE UPLOADED

=> d l1
L1 HAS NO ANSWERS
L1 STR

Cb [2]

Hy [1]



G1 [@1],[@2]

Structure attributes must be viewed using STN Express query preparation.

```
=> s l1 sss sam
SAMPLE SEARCH INITIATED 15:37:23 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -   2279 TO ITERATE

 43.9% PROCESSED    1000 ITERATIONS                                 8 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:        42717 TO    48443
PROJECTED ANSWERS:             108 TO      620

L2             8 SEA SSS SAM L1

=> => s l1 sss ful
FULL SEARCH INITIATED 15:39:16 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -  45605 TO ITERATE

100.0% PROCESSED   45605 ITERATIONS                             215 ANSWERS
SEARCH TIME: 00.00.02

L3           215 SEA SSS FUL L1

=>
Uploading C:\Program Files\Common Files\System\Mapi\1033\NT\10009607 (amd - sub).str
```





chain nodes :
6 8
ring nodes :
1 2 3 4 5
chain bonds :
5-6 6-8
ring bonds :
1-2 1-5 2-3 3-4 4-5
exact/norm bonds :
1-2 1-5 2-3 3-4 4-5 5-6 6-8
isolated ring systems :
containing 1 :

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:CLASS 8:CLASS

L4 STRUCTURE UPLOADED

=> d l4
L4 HAS NO ANSWERS
L4 STR



Structure attributes must be viewed using STN Express query preparation.

=> s l4 sub=l3 sss sam
SAMPLE SUBSET SEARCH INITIATED 15:41:34 FILE 'REGISTRY'

```
SAMPLE SUBSET SCREEN SEARCH COMPLETED -      4 TO ITERATE

100.0% PROCESSED       4 ITERATIONS                                4 ANSWERS
SEARCH TIME: 00.00.02

PROJECTIONS (WITHIN SPECIFIED SUBSET):          ONLINE  **COMPLETE**
PROJECTED ITERATIONS (WITHIN SPECIFIED SUBSET):          4 TO      200
PROJECTED ANSWERS (WITHIN SPECIFIED SUBSET):             4 TO      200

L5             4 SEA SUB=L3 SSS SAM L4

=> s l4 sub=l3 sss ful
FULL SUBSET SEARCH INITIATED 15:41:42 FILE 'REGISTRY'
FULL SUBSET SCREEN SEARCH COMPLETED -     56 TO ITERATE

100.0% PROCESSED      56 ITERATIONS                               40 ANSWERS
SEARCH TIME: 00.00.01

L6            40 SEA SUB=L3 SSS FUL L4

=>
Uploading C:\Program Files\Common Files\System\Mapi\1033\NT\10009607 (amd-sub2).str
```






```
chain nodes :
6  8  9
ring nodes :
1  2  3  4  5
ring/chain nodes :
10
chain bonds :
1-10  4-8  5-6  8-9
ring bonds :
1-2  1-5  2-3  3-4  4-5
exact/norm bonds :
1-2  1-5  1-10  2-3  3-4  4-5  5-6
exact bonds :
4-8  8-9
isolated ring systems :
containing 1 :


Match level :
1:Atom  2:Atom  3:Atom  4:Atom  5:Atom  6:CLASS  8:CLASS  9:CLASS  10:CLASS



L7       STRUCTURE UPLOADED
```

```
=> d l7
L7 HAS NO ANSWERS
L7                STR
```



Structure attributes must be viewed using STN Express query preparation.

```
=> s l7 sub=l3 sss sam
SAMPLE SUBSET SEARCH INITIATED 15:43:06 FILE 'REGISTRY'
SAMPLE SUBSET SCREEN SEARCH COMPLETED -     16 TO ITERATE

100.0% PROCESSED      16 ITERATIONS                              2 ANSWERS
SEARCH TIME: 00.00.01

PROJECTIONS (WITHIN SPECIFIED SUBSET):          ONLINE  **COMPLETE**
PROJECTED ITERATIONS (WITHIN SPECIFIED SUBSET):          80 TO      560
PROJECTED ANSWERS (WITHIN SPECIFIED SUBSET):              2 TO      124

L8             2 SEA SUB=L3 SSS SAM L7

=> s l7 sub=l3 sss ful
FULL SUBSET SEARCH INITIATED 15:43:12 FILE 'REGISTRY'
FULL SUBSET SCREEN SEARCH COMPLETED -    215 TO ITERATE

100.0% PROCESSED     215 ITERATIONS                             46 ANSWERS
SEARCH TIME: 00.00.01

L9            46 SEA SUB=L3 SSS FUL L7

=> s l6 or l9
L10          86 L6 OR L9

=> s l3 not l10
L11         129 L3 NOT L10

=> => s l11
L12          31 L11

=> d l12 1-31 bib,ab,hitstr
```

L12 ANSWER 1 OF 31 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2001:879054 CAPLUS
DN 136:294766
TI Solid-phase synthesis of bis-cyclic guanidines from tripeptides
AU Acharya, Achyuta N.; Ostresh, John M.; Houghten, Richard A.
CS Torrey Pines Institute for Molecular Studies, San Diego, CA, 92121, USA
SO Tetrahedron (2001), 57(50), 9911-9914
CODEN: TETRAB; ISSN: 0040-4020
PB Elsevier Science Ltd.
DT Journal
LA English
OS CASREACT 136:294766
AB An efficient method for the solid-phase synthesis of bis-cyclic guanidines, e.g. I, from reduced tripeptides is described. The exhaustive reduction of the tripeptides generated tetra-amines that on treatment with cyanogen bromide, afforded bis-cyclic guanidines having three sep. variable positions.
IT **409083-22-3P 409083-27-8P 409083-31-4P**
409083-35-8P 409083-40-5P 409083-44-9P
409083-46-1P 409083-48-3P 409083-50-7P
409083-52-9P 409083-54-1P 409083-55-2P
409083-56-3P
RL: SPN (Synthetic preparation); PREP (Preparation)
(solid phase synthesis of bis-cyclic guanidines from tripeptides via cyclization)
RN 409083-22-3 CAPLUS
CN 1H-Imidazol-2-amine, 1-[1-[(2-amino-5-cyclohexyl-4,5-dihydro-1H-imidazol-1-yl)methyl]-2-phenylethyl]-4,5-dihydro-4-methyl- (9CI) (CA INDEX NAME)



RN 409083-27-8 CAPLUS
CN 1H-Imidazol-2-amine, 1-[1-[[2-amino-4,5-dihydro-5-(phenylmethyl)-1H-imidazol-1-yl]methyl]-2-phenylethyl]-4,5-dihydro-4-methyl- (9CI) (CA INDEX NAME)



RN 409083-31-4 CAPLUS
CN 1H-Imidazol-2-amine, 1-[1-[[2-amino-4,5-dihydro-5-(1-methylethyl)-1H-

imidazol-1-yl]methyl]-2-phenylethyl]-4,5-dihydro-4-methyl- (9CI) (CA INDEX NAME)



RN 409083-35-8 CAPLUS
CN 1H-Imidazol-2-amine, 1-[1-[[2-amino-4,5-dihydro-5-(2-naphthalenylmethyl)-1H-imidazol-1-yl]methyl]-2-phenylethyl]-4,5-dihydro-4-methyl- (9CI) (CA INDEX NAME)



RN 409083-40-5 CAPLUS
CN 1H-Imidazol-2-amine, 1-[1-[[2-amino-5-[(4-chlorophenyl)methyl]-4,5-dihydro-1H-imidazol-1-yl]methyl]-2-phenylethyl]-4,5-dihydro-4-methyl- (9CI) (CA INDEX NAME)



RN 409083-44-9 CAPLUS

CN 1H-Imidazol-2-amine, 1-[2-[2-amino-4,5-dihydro-5-(phenylmethyl)-1H-imidazol-1-yl]-1-methylethyl]-4,5-dihydro-4-methyl- (9CI) (CA INDEX NAME)



RN 409083-46-1 CAPLUS
CN 1H-Imidazol-2-amine, 1-[2-[2-amino-4,5-dihydro-5-(phenylmethyl)-1H-imidazol-1-yl]-1-[(4-chlorophenyl)methyl]ethyl]-4,5-dihydro-4-methyl- (9CI) (CA INDEX NAME)



RN 409083-48-3 CAPLUS
CN 1H-Imidazol-2-amine, 1-[2-[2-amino-4,5-dihydro-5-(phenylmethyl)-1H-imidazol-1-yl]-1-[(4-methoxyphenyl)methyl]ethyl]-4,5-dihydro-4-methyl- (9CI) (CA INDEX NAME)



RN 409083-50-7 CAPLUS
CN 1H-Imidazol-2-amine, 1-[1-[[2-amino-4,5-dihydro-5-(phenylmethyl)-1H-imidazol-1-yl]methyl]-2-phenylethyl]-4,5-dihydro-4-(2-methylpropyl)- (9CI)

(CA INDEX NAME)



RN 409083-52-9 CAPLUS
CN 1H-Imidazol-2-amine, 1-[1-[[2-amino-4,5-dihydro-5-(phenylmethyl)-1H-imidazol-1-yl]methyl]-2-phenylethyl]-4,5-dihydro-4-propyl- (9CI) (CA INDEX NAME)



RN 409083-54-1 CAPLUS
CN 1H-Imidazol-2-amine, 1-[1-[[2-amino-4,5-dihydro-5-(phenylmethyl)-1H-imidazol-1-yl]methyl]-2-phenylethyl]-4-cyclohexyl-4,5-dihydro- (9CI) (CA INDEX NAME)



RN 409083-55-2 CAPLUS
CN 1H-Imidazole-4-methanol, 2-amino-1-[1-[(2-amino-5-butyl-4,5-dihydro-1H-imidazol-1-yl)methyl]-2-phenylethyl]-4,5-dihydro-α-methyl- (9CI) (CA INDEX NAME)



RN 409083-56-3 CAPLUS
CN 1H-Imidazole-1-propanol, 2-amino-β-(2-amino-4,5-dihydro-4-methyl-1H-imidazol-1-yl)-4,5-dihydro-5-propyl- (9CI) (CA INDEX NAME)



RE.CNT 28 THERE ARE 28 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 2 OF 31 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2001:791905 CAPLUS
DN 135:331418
TI Preparation of thiazoles as agonists or modulators of nicotinic acetylcholine α4β2 receptor
IN Imoto, Masahiro; Iwanami, Tatsuya; Akabane, Minako; Tani, Yoshihiro
PA Suntory, Ltd., Japan
SO Jpn. Kokai Tokkyo Koho, 19 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 2001302635	A2	20011031	JP 2000-120975	20000421
	WO 2001081326	A1	20011101	WO 2001-JP3377	20010420
	W: AU, CA, CN, KR, US				
	RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR				
	AU 2001048798	A5	20011107	AU 2001-48798	20010420
	EP 1185521	A1	20020313	EP 2001-921931	20010420
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
	US 2003134848	A1	20030717	US 2001-9607	20011121
PRAI	JP 2000-120975	A	20000421		
	WO 2001-JP3377	W	20010420		

OS MARPAT 135:331418
AB Title compds. I [A = (un)substituted alkyl, aryl, heterocyclyl; B1, B2 = H, alkyl, OH; CB1B2 may form carbonyl; X = O, S, C, N; dotted line represents optional bond; n = 1-2; if X = O, then YX = CH2CH2O, (CH2)3O; if X = S, then YX = CH2CH2S, CR1:CR2S; ; if X = C, then YX = (CH2)3, (CH2)4, CH:CR3CR4:CH, N:CR5CR6:CH; if X = N, then YX = CH2CH2NH, (CH2)3N, CR7:CR8N:, CR9:CR10CR11:N; R1-R11 = H, halo, (un)substituted alkyl, aryl, heterocyclyl] or their pharmaceutically acceptable salts, useful for treatment of Alzheimer's disease, Parkinson's disease, cerebrovascular dementia, Tourette syndrome, neurosis, anxiety, and schizophrenia and are prepared 2-Amino-5-methyl-2-thiazoline was reacted with 5-(2-bromoethyl)-2-chloropyridine in acetonitrile at 90° for 14 h to give 61.2% 3-[2-(6-chloro-3-pyridyl)ethyl]-2-imino-5-methyl-2,3-dihydrothiazole, which was reacted with fumaric acid to give a salts showing good affinity to acetylcholine α4β2 receptor.
IT **369609-24-5P 369609-32-5P 369609-37-0P**
369609-40-5P 369609-45-0P 369609-47-2P
369609-50-7P 369609-52-9P 369609-55-2P
369609-57-4P 369609-58-5P 369609-60-9P
369609-64-3P 369609-67-6P 369609-68-7P
369609-69-8P 369609-70-1P 369609-71-2P
369609-73-4P 369609-85-8P 369609-91-6P
369609-94-9P 369609-95-0P 369610-00-4P
369610-04-8P 369610-05-9P 369610-06-0P
369610-08-2P 369610-11-7P 369610-12-8P
369610-14-0P 369610-17-3P 369610-18-4P
369610-20-8P 369610-21-9P 369610-22-0P
369610-24-2P 369610-26-4P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of thiazoles as agonists or modulators of nicotinic

acetylcholine α4β2 receptor)

RN 369609-24-5 CAPLUS

CN 1H-Imidazol-2-amine, 1-[2-(6-chloro-3-pyridinyl)ethyl]- (9CI) (CA INDEX NAME)



RN 369609-32-5 CAPLUS

CN 1H-Imidazol-2-amine, 1-[2-(6-methyl-3-pyridinyl)ethyl]- (9CI) (CA INDEX NAME)



RN 369609-37-0 CAPLUS

CN 1H-Imidazol-2-amine, 1-[2-(5,6-dichloro-3-pyridinyl)ethyl]- (9CI) (CA INDEX NAME)



RN 369609-40-5 CAPLUS
CN 1H-Imidazol-2-amine, 1-[2-(3-pyridinyl)ethyl]- (9CI) (CA INDEX NAME)



RN 369609-45-0 CAPLUS
CN 1H-Imidazol-2-amine, 1-[2-(4-chlorophenyl)ethyl]- (9CI) (CA INDEX NAME)



RN 369609-47-2 CAPLUS
CN 1H-Imidazol-2-amine, 1-[2-(2-pyridinyl)ethyl]- (9CI) (CA INDEX NAME)



RN 369609-50-7 CAPLUS
CN 1H-Imidazol-2-amine, 1-[2-(4-pyridinyl)ethyl]- (9CI) (CA INDEX NAME)



RN 369609-52-9 CAPLUS
CN 1H-Imidazol-2-amine, 1-[2-(6-chloro-3-pyridinyl)ethyl]-4,5-dimethyl- (9CI) (CA INDEX NAME)



RN 369609-55-2 CAPLUS
CN 1H-Imidazol-2-amine, 1-[2-(2-chloro-5-thiazolyl)ethyl]- (9CI) (CA INDEX NAME)



RN 369609-57-4 CAPLUS
CN 1H-Imidazol-2-amine, 1-[2-(5-bromo-3-pyridinyl)ethyl]- (9CI) (CA INDEX NAME)



RN 369609-58-5 CAPLUS
CN Phenol, 4-[2-(2-amino-1H-imidazol-1-yl)ethyl]- (9CI) (CA INDEX NAME)



RN 369609-60-9 CAPLUS
CN 1H-Imidazol-2-amine, 1-[2-(5-methyl-3-pyridinyl)ethyl]- (9CI) (CA INDEX

NAME)



RN 369609-64-3 CAPLUS
CN 1H-Imidazol-2-amine, 1-[2-(5-pyrimidinyl)ethyl]- (9CI) (CA INDEX NAME)



RN 369609-67-6 CAPLUS
CN 1H-Imidazol-2-amine, 1-[2-(3-pyridazinyl)ethyl]- (9CI) (CA INDEX NAME)



RN 369609-68-7 CAPLUS
CN 1H-Imidazol-2-amine, 1-(2-pyrazinylethyl)- (9CI) (CA INDEX NAME)



RN 369609-69-8 CAPLUS
CN Phenol, 4-[[2-[2-(2-amino-1H-imidazol-1-yl)ethyl]phenyl]thio]- (9CI) (CA INDEX NAME)



RN 369609-70-1 CAPLUS
CN 1H-Imidazol-2-amine, 1-[2-[2-[(4-methoxyphenyl)thio]phenyl]ethyl]- (9CI) (CA INDEX NAME)



RN 369609-71-2 CAPLUS
CN 1H-Imidazol-2-amine, 1-[2-(4-pyridazinyl)ethyl]- (9CI) (CA INDEX NAME)



RN 369609-73-4 CAPLUS
CN 1H-Imidazol-2-amine, 1-[2-(4-chloro-5-pyrimidinyl)ethyl]- (9CI) (CA INDEX NAME)



RN 369609-85-8 CAPLUS
CN 1H-Imidazol-2-amine, 1-[2-(6-chloro-3-pyridinyl)ethyl]-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 369609-24-5
CMF C10 H11 Cl N4



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



RN 369609-91-6 CAPLUS
CN 1H-Imidazol-2-amine, 1-[2-(6-methyl-3-pyridinyl)ethyl]-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 369609-32-5
CMF C11 H14 N4



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



RN 369609-94-9 CAPLUS
CN 1H-Imidazol-2-amine, 1-[2-(5,6-dichloro-3-pyridinyl)ethyl]-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 369609-37-0
CMF C10 H10 Cl2 N4



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



RN 369609-95-0 CAPLUS
CN 1H-Imidazol-2-amine, 1-[2-(3-pyridinyl)ethyl]-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 369609-40-5
CMF C10 H12 N4



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



RN 369610-00-4 CAPLUS
CN 1H-Imidazol-2-amine, 1-[2-(4-chlorophenyl)ethyl]-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 369609-45-0
CMF C11 H12 Cl N3



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



RN 369610-04-8 CAPLUS
CN 1H-Imidazol-2-amine, 1-[2-(2-pyridinyl)ethyl]-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 369609-47-2
CMF C10 H12 N4



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



RN 369610-05-9 CAPLUS
CN 1H-Imidazol-2-amine, 1-[2-(4-pyridinyl)ethyl]-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 369609-50-7
CMF C10 H12 N4



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



RN 369610-06-0 CAPLUS
CN 1H-Imidazol-2-amine, 1-[2-(6-chloro-3-pyridinyl)ethyl]-4,5-dimethyl-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 369609-52-9
CMF C12 H15 Cl N4



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



RN 369610-08-2 CAPLUS
CN 1H-Imidazol-2-amine, 1-[2-(2-chloro-5-thiazolyl)ethyl]-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 369609-55-2
CMF C8 H9 Cl N4 S



CM 2

CRN 110-17-8

CMF C4 H4 O4

Double bond geometry as shown.



RN 369610-11-7 CAPLUS
CN 1H-Imidazol-2-amine, 1-[2-(5-bromo-3-pyridinyl)ethyl]-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 369609-57-4
CMF C10 H11 Br N4



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



RN 369610-12-8 CAPLUS
CN Phenol, 4-[2-(2-amino-1H-imidazol-1-yl)ethyl]-, (2E)-2-butenedioate (1:1) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 369609-58-5
CMF C11 H13 N3 O



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



RN 369610-14-0 CAPLUS
CN 1H-Imidazol-2-amine, 1-[2-(5-methyl-3-pyridinyl)ethyl]-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 369609-60-9
CMF C11 H14 N4



CM 2

CRN 110-17-8

CMF C4 H4 O4

Double bond geometry as shown.



RN 369610-17-3 CAPLUS
CN 1H-Imidazol-2-amine, 1-[2-(5-pyrimidinyl)ethyl]-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 369609-64-3
CMF C9 H11 N5



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



RN 369610-18-4 CAPLUS
CN 1H-Imidazol-2-amine, 1-[2-(3-pyridazinyl)ethyl]-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 369610-20-8 CAPLUS
CN 1H-Imidazol-2-amine, 1-(2-pyrazinylethyl)-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 369609-68-7
CMF C9 H11 N5



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



RN 369610-21-9 CAPLUS
CN Phenol, 4-[[2-[2-(2-amino-1H-imidazol-1-yl)ethyl]phenyl]thio]-, (2E)-2-butenedioate (2:1) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 369609-69-8
CMF C17 H17 N3 O S



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



RN 369610-22-0 CAPLUS
CN 1H-Imidazol-2-amine, 1-[2-[2-[(4-methoxyphenyl)thio]phenyl]ethyl]-, (2E)-2-butenedioate (2:1) (9CI) (CA INDEX NAME)

CM 1

CRN 369609-70-1
CMF C18 H19 N3 O S



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



RN 369610-24-2 CAPLUS
CN 1H-Imidazol-2-amine, 1-[2-(4-pyridazinyl)ethyl]-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 369609-71-2
CMF C9 H11 N5



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



RN 369610-26-4 CAPLUS
CN 1H-Imidazol-2-amine, 1-[2-(4-chloro-5-pyrimidinyl)ethyl]-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 369609-73-4
CMF C9 H10 Cl N5



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



L12 ANSWER 3 OF 31 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2001:780862 CAPLUS
DN 135:331423
TI Preparation of 5-substituted tetralones as inhibitors of ras farnesyl transferase for treatment of proliferative diseases
IN Denny, William Alexander; Hutchings, Richard H.; Johnson, Douglas S.; Kaltenbronn, James Stanley; Lee, Ho Huat; Leonard, Daniele Marie; Milbank, Jared Bruce John; Repine, Joseph Thomas; Rewcastle, Gordon William; White, Andrew David
PA Warner-Lambert Co., USA
SO PCT Int. Appl., 358 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001079180	A2	20011025	WO 2001-US12490	20010416
	WO 2001079180	A3	20020523		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	BR 2001010142	A	20030121	BR 2001-10142	20010416
	EP 1276725	A2	20030122	EP 2001-927121	20010416
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	JP 2003531143	T2	20031021	JP 2001-576781	20010416
	US 2004044057	A1	20040304	US 2003-257301	20030519
PRAI	US 2000-197485P	P	20000417		
	WO 2001-US12490	W	20010416		

OS MARPAT 135:331423
AB Title compds. I [wherein W = CH2 or CH2CH2; R3 = H, alkyl, or (un)substituted Ph; R3a = H or alkyl; provided that R3 and R3a cannot both be H and that when R3 = (un)substituted Ph, then R3a = H; X = halo, NH2, alkyl, alkenyl, heteroaryl, CH2OR6, CH2NR6R6a, CH2SR6, CH2CH2CO2R6, or (un)substituted aryl, or (hetero)arylalkyl; R6 = H, (cyclo)alkyl, alkenyl, benzyl, or (un)substituted Ph; R6a = H or alkyl; Y = O or S; R5 = H, alkyl, or NH2; and pharmaceutically acceptable salts, esters, amides, and prodrugs thereof] were prepared and formulated as farnesyl transferase enzyme inhibitors. For example, coupling of 5-chloromethyl-6-hydroxy-2,3,4-trihydronaphthalen-1-one with thiophenol using diisopropylamine in THF (58%), followed by addition of (R)-2-imidazol-1-yl-1-phenylethanol in the presence of PPh3 and di-Et azodicarboxylate in THF (31%), gave II. The latter inhibited farnesyl protein transferase (FPT) with IC50 of 0.3 nM. I are useful for treating and preventing uncontrolled or abnormal proliferation of tissues, such as cancer, atherosclerosis, restenosis, and psoriasis (no data).
IT **368882-96-6P**, 6-[2-(2-Aminoimidazol-1-yl)-1-phenylethoxy]-5-phenethyl-3,4-dihydro-2H-naphthalen-1-one
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of 5-substituted tetralones as Ras farnesyl transferase inhibitors for treatment of proliferative diseases, such as cancer, atherosclerosis, restenosis, and psoriasis)

RN 368882-96-6 CAPLUS

CN 1(2H)-Naphthalenone, 6-[2-(2-amino-1H-imidazol-1-yl)-1-phenylethoxy]-3,4-dihydro-5-(2-phenylethyl)- (9CI) (CA INDEX NAME)



L12 ANSWER 4 OF 31 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2001:680327 CAPLUS
DN 136:20041
TI A Novel Approach for the Solid-Phase Synthesis of Substituted Cyclic Guanidines, Their Respective Bis Analogs, and N-Acylated Guanidines from N-Acylated Amino Acid Amides
AU Acharya, Achyuta N.; Ostresh, John M.; Houghten, Richard A.
CS Torrey Pines Institute for Molecular Studies, San Diego, CA, 92121, USA
SO Journal of Combinatorial Chemistry (2001), 3(6), 578-589
CODEN: JCCHFF; ISSN: 1520-4766
PB American Chemical Society
DT Journal
LA English
AB An efficient method for the solid-phase synthesis of cyclic guanidines from N-acylated amino acid amides, bis cyclic guanidines from N-acylated dipeptides derived from orthogonally protected diamino acids, and N-acylated guanidines from disubstituted cyclic guanidines is described. The exhaustive reduction of N-acylated amino acid amides yields diamines that on treatment with cyanogen bromide lead to the formation of cyclic guanidines. Resin-bound orthogonally protected diamino acids (i.e., Nα-Fmoc-Nx-(Boc)-diamino acid, x = β, γ, δ, ε) were N-acylated following removal of the Fmoc group. Removal of the Boc functionality from the side chain then generated a primary amine. Subsequent coupling of Boc amino acids, followed by removal of the Boc group, generated dipeptides that were N-acylated. Exhaustive reduction of amide bonds of the N-acylated dipeptides generated tetraamines having four secondary amines, which upon cyclization with cyanogen bromide afforded the resin-bound trisubstituted bis cyclic guanidines. Treatment of the resin-bound disubstituted cyclic guanidines with carboxylic acids gave N-acylated guanidines. On the basis of their high yield and purity, bis cyclic guanidines derived from Nα-Fmoc-Nε-Boc-lysine and N-acylated guanidines were chosen for preparation of mixture-based combinatorial libraries. Details of the preparation of these positional scanning libraries using the "libraries from libraries" concept are presented.
IT **375395-35-0P 375395-38-3P 375395-39-4P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(solid-phase synthesis of cyclic guanidines from N-acylated amino acid amides, bis cyclic guanidines from N-acylated dipeptides, and N-acylated guanidines)
RN 375395-35-0 CAPLUS
CN 1H-Imidazol-2-amine, 4,5-dihydro-1-(2-phenylethyl)-5-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 375395-38-3 CAPLUS
CN 1H-Imidazol-2-amine, 4,5-dihydro-5-(2-methylpropyl)-1-(2-phenylethyl)- (9CI) (CA INDEX NAME)



RN 375395-39-4 CAPLUS
CN 1H-Imidazol-2-amine, 4,5-dihydro-5-methyl-1-(2-phenylethyl)- (9CI) (CA INDEX NAME)



RE.CNT 53 THERE ARE 53 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 5 OF 31 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2001:680326 CAPLUS
DN 136:5942
TI Solid-Phase Synthesis of 2,3,5-Trisubstituted 4H-Imidazolones
AU Yu, Yongping; Ostresh, John M.; Houghten, Richard A.
CS Torrey Pines Institute for Molecular Studies, San Diego, CA, 92121, USA
SO Journal of Combinatorial Chemistry (2001), 3(6), 521-523
CODEN: JCCHFF; ISSN: 1520-4766
PB American Chemical Society
DT Journal
LA English
OS CASREACT 136:5942
AB 2,3,4-Trisubstituted 4H-imidazolones were synthesized from resin-bound amino acids . The reaction of resin-bound amino acids with Ph isothiocyanate derivs. gave resin-bound thioureas that were treated with HgCl2 and primary or secondary amines to give resin-bound guanidines. For example, resin-bound amine was treated with N-(tert-butoxycarbonyl)-DL-valine to give a resin-bound amino acid which was deprotected and subsequently treated with 4-chlorophenyl isothiocyanate. N-methylbenzeneethanamine was added to the thiourea derivative thus obtained to give a resin-bound guanidine. Treatment of the latter with HF in anisole gave 3-(4-chlorophenyl)-3,5-dihydro-5-(1-methylethyl)-1-[methyl(2-phenylethyl)amino]-4H-imidazol-4-one.
IT **375396-22-8P 375396-24-0P 375396-26-2P**
375396-29-5P 375396-31-9P 375396-33-1P
RL: SPN (Synthetic preparation); PREP (Preparation)
(solid-phase synthesis of 2,3,5-trisubstituted 4H-imidazolones)
RN 375396-22-8 CAPLUS
CN 4H-Imidazol-4-one, 3,5-dihydro-2-(phenylamino)-3-(2-phenylethyl)-5-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 375396-24-0 CAPLUS
CN 4H-Imidazol-4-one, 5-[(4-fluorophenyl)methyl]-3,5-dihydro-2-(phenylamino)-3-(2-phenylethyl)- (9CI) (CA INDEX NAME)



RN 375396-26-2 CAPLUS
CN 4H-Imidazol-4-one, 3,5-dihydro-3-(2-phenylethyl)-5-(phenylmethyl)-2-[[4-(trifluoromethyl)phenyl]amino]- (9CI) (CA INDEX NAME)



RN 375396-29-5 CAPLUS
CN 4H-Imidazol-4-one, 3,5-dihydro-5-(1-methylethyl)-2-(phenylamino)-3-(2-phenylethyl)- (9CI) (CA INDEX NAME)



RN 375396-31-9 CAPLUS
CN 4H-Imidazol-4-one, 3,5-dihydro-2-[(4-nitrophenyl)amino]-3-(2-phenylethyl)-5-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 375396-33-1 CAPLUS
CN 4H-Imidazol-4-one, 3,5-dihydro-2-[(4-methylphenyl)amino]-3-(2-phenylethyl)-5-(phenylmethyl)- (9CI) (CA INDEX NAME)



RE.CNT 36 THERE ARE 36 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 6 OF 31 CAPLUS COPYRIGHT 2004 ACS on STN
AN 1996:365530 CAPLUS
DN 125:33677
TI Method of preparation of novel derivatives of 1-[(4-phenylpiperazino)alkyl]ethylenediamine and 1-[(4-phenylpiperazino)alkyl)-2-iminoimidazolidine
IN Tkaczynski, Tadeusz; Kulinski, Tomasz
PA Akademia Medyczna, Pol.
SO Pol., 4 pp.
CODEN: POXXA7
DT Patent
LA Polish
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI PL 167650	B1	19951031	PL 1992-297049	19921216
PRAI PL 1992-297049		19921216		

OS CASREACT 125:33677; MARPAT 125:33677
AB Title compds. I and II [R = H, halo, alkyl, etc.; n = 2, 3], useful as intermediates in pharmaceutical industry, were prepared Alkylation of NH2(CH2)2NH2 with 1-(2-methylphenyl)-4-(β-chloroethyl)piperazine in the presence of KI at 100° afforded I [R = 2-Me; n = 2]. Treatment of I [R = 4-Me; n = 2] with BrCN in C6H6 gave II.HBr [R = 4-Me; n = 2].
IT **166772-87-8P**
RL: IMF (Industrial manufacture); SPN (Synthetic preparation); PREP (Preparation)
(method of preparation of novel derivs. of 1-[(4-phenylpiperazino)alkyl]ethylenediamine and 1-[(4-phenylpiperazino)alkyl)-2-iminoimidazolidine)
RN 166772-87-8 CAPLUS
CN 1H-Imidazol-2-amine, 4,5-dihydro-1-[2-[4-(4-methylphenyl)-1-piperazinyl]ethyl]-, monohydrobromide (9CI) (CA INDEX NAME)



L12 ANSWER 7 OF 31 CAPLUS COPYRIGHT 2004 ACS on STN
AN 1996:294187 CAPLUS
DN 125:58392
TI Preparation of heterocycles using functionalized heterocumulenes. 5. Iodocyclization of 3-alkynyl- and 3-allenyl-2-(substituted amino)-1-imidazolin-4-ones
AU Noguchi, Michihiko; Okada, Hiroshi; Watanabe, Masanori; Okuda, Kumi; Nakamura, Osamu
CS Department Applied Chemistry, Yamaguchi University, Ube, 755, Japan
SO Tetrahedron (1996), 52(19), 6581-6590
CODEN: TETRAB; ISSN: 0040-4020
PB Elsevier
DT Journal
LA English
OS CASREACT 125:58392
AB The iodocyclization of 3-alkynyl-2-(substituted amino)-1-imidazolin-4-ones proceeded in regio- and stereoselective manner to give bicyclic guanidines, imidazo[1,2-a]imidazole and/or imidazo[1,2-a]pyrimidine. The regiochem. and reactivity of the cyclization were interpretable by the PM3 MO calcns. of the iodonium ion intermediates.
IT **177979-22-5 177979-23-6**
RL: PRP (Properties)
(Frontier orbital energy levels and electron densities of)
RN 177979-22-5 CAPLUS
CN Iodirenium, [2-[4,5-dihydro-4,4-dimethyl-5-oxo-2-(phenylamino)-1H-imidazol-1-yl]ethyl]- (9CI) (CA INDEX NAME)



RN 177979-23-6 CAPLUS
CN Iodirenium, [2-[4,5-dihydro-4,4-dimethyl-2-[[(4-methylphenyl)sulfonyl]amino]-5-oxo-1H-imidazol-1-yl]ethyl]- (9CI) (CA INDEX NAME)



L12 ANSWER 9 OF 31 CAPLUS COPYRIGHT 2004 ACS on STN
AN 1994:605349 CAPLUS
DN 121:205349
TI Preparation of triazole derivatives and other heterocycles as pesticides
IN Kishimoto, Takashi; Shibata, Yasushi; Matsuda, Michihiko; Hatano, Renpei
PA Nippon Soda Co., Ltd., Japan
SO PCT Int. Appl., 75 pp.
CODEN: PIXXD2
DT Patent
LA Japanese
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9406765	A1	19940331	WO 1993-JP1321	19930916
	W: AT, AU, BB, BG, BR, CA, CH, CZ, DE, DK, ES, FI, GB, HU, JP, KR, LK, LU, MG, MN, MW, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SK, UA, US				
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	AU 9349842	A1	19940412	AU 1993-49842	19930916
PRAI	JP 1992-272454	A	19920917		
	WO 1993-JP1321	W	19930916		

OS MARPAT 121:205349
AB Title compds. [I; Y = N, CR3; R3 = H, halo, (un)substituted alkyl, etc.; Z = nitro, cyano; X = O, S, NR4; R1, R2, R4 = H, (un)substituted alkyl, (un)substituted alkenyl, (un)substituted alkynyl, etc.; the ring containing N and Q is a 4- to 6-membered ring; l = 0, 1; m = 2, 3, 4; n = 1, 2, 3] are prepared A mixture of 2-(nitroimino)imidazolidine, DMF, NaH, and 3-chloro-1-(chloromethyl)-1,2,4-triazole was stirred at room temperature overnight to give the title compound II. This at 125 ppm showed 100% control against aphids. Agrochem. prepns. containing I are described.
IT **157395-44-3P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of, for pest control)
RN 157395-44-3 CAPLUS
CN 1H-Imidazol-2-amine, 4,5-dihydro-N-nitro-1-[2-(1H-1,2,4-triazol-1-yl)ethyl]- (9CI) (CA INDEX NAME)



L12 ANSWER 10 OF 31 CAPLUS COPYRIGHT 2004 ACS on STN
AN 1993:472239 CAPLUS
DN 119:72239
TI Preparation of alkylamine analogs as pesticides.
IN Kishimoto, Takashi; Saso, Haruo; Yamada, Yasuo; Matsuda, Michihiko; Takakusa, Nobuo
PA Nippon Soda Co., Ltd., Japan
SO PCT Int. Appl., 46 pp.
CODEN: PIXXD2
DT Patent
LA Japanese
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9304032	A1	19930304	WO 1992-JP1051	19920820
	W: US				
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, SE				
	JP 05310650	A2	19931122	JP 1992-241344	19920818
PRAI	JP 1991-235487		19910822		
	JP 1991-348451		19911205		

OS MARPAT 119:72239
AB R1-(X)l-C(:YZ)-NR2(CH2)n-Q [I; R1 = (un)substituted alkyl; R2 = H, (un)substituted alkyl, COR3; X = NR4; R3, R4 = H, (un)substituted alkyl; Y = CH, N; Z = CN, NO2; Q = radical containing a double bond or a triple bond; l = 0, 1; n = 0-7 integer] and R1-(X)l-C(:YZ)-AR5 [II; A = H, S; R5 = alkyl], useful as insecticides and acaricides, are prepared H2S was introduced into a solution of MeNH-C(:NNO2)NH-(CH2)2-CN in pyridine containing Et3N at 40-40° for 2 h to give I [R1(X)l = MeNH, Y = N, Z = NO2, n = 2, Q = CO2Et], which at 125 ppm showed 100% control of cotton aphid. Pesticidal formulations containing I or II are described.
IT **149018-57-5P 149018-58-6P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of, as pesticides)
RN 149018-57-5 CAPLUS
CN 1H-Imidazol-2-amine, 4,5-dihydro-N-nitro-1-[2-[2-[(trimethylsilyl)ethynyl]phenyl]ethyl]- (9CI) (CA INDEX NAME)



RN 149018-58-6 CAPLUS
CN 1H-Imidazol-2-amine, 1-[2-(2-ethynylphenyl)ethyl]-4,5-dihydro-N-nitro- (9CI) (CA INDEX NAME)


N
NH—NO2
N
CH2
CH2
C≡CH

L12 ANSWER 11 OF 31 CAPLUS COPYRIGHT 2004 ACS on STN
AN 1993:6982 CAPLUS
DN 118:6982
TI Preparation of [(heterocyclyl)(alkyl)]phenyl amidines and guanidines as hypoglycemics.
IN Gopalan, Balasubramanian
PA Boots Co., PLC, UK
SO Faming Zhuanli Shenqing Gongkai Shuomingshu, 123 pp.
CODEN: CNXXEV
DT Patent
LA Chinese
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	CN 1057648	A	19920108	CN 1990-103295	19900629
	CN 1037346	B	19980211		
PRAI	CN 1990-103295		19900629		

OS CASREACT 118:6982; MARPAT 118:6982
AB The title compds. [I; R1, R2 = (methoxy) aliphatic hydrocarbyl, cycloalkyl; or NR1R2 = N-containing heterocyclyl; R3 = alkyl, cycloalkyl, (substituted) amino; R5 = (methoxy) aliphatic hydrocarbyl; R6 = H, (substituted) alkyl, cycloalkyl; R7 = H,alkyl, halo, methoxy, CO2Me, SO2Me; R3R5 may form part of a ring; with provisos] are prepared E.g., 1-benzyl-3-methyl-2-pyrrolidinone in benzene containing POCl3 was heated with 4-(2-aminophenyl)morpholine at 70° for 24 h to give 4-[2-(1-benzyl-3-methyl-2-pyrrolidinylideneamino)phenyl]morpholine. This decreased the blood sugar level by ≥25% in rats 2 or 4 h after they were injected s.c. with glucose. Pharmaceuticals containing I were formulated.
IT **131677-60-6P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of, as hypoglycemic)
RN 131677-60-6 CAPLUS
CN 1H-Imidazol-2-amine, 4,5-dihydro-N-[2-(4-morpholinyl)phenyl]-1-(2-phenylethyl)- (9CI) (CA INDEX NAME)



L12 ANSWER 12 OF 31 CAPLUS COPYRIGHT 2004 ACS on STN
AN 1991:185242 CAPLUS
DN 114:185242
TI Preparation of N-aryl-N-(4-heterocyclic alkyl)piperidinyl)amides
IN Bagley, Jerome R.; Lalinde, Nhora Lucia; Huang, Bao Shan; Spencer, H. Kenneth
PA BOC Inc., USA
SO Eur. Pat. Appl., 51 pp.
CODEN: EPXXDW
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 396282	A2	19901107	EP 1990-304210	19900419
	EP 396282	A3	19920108		
	R: DE, ES, FR, GB, IT				
	US 5053411	A	19911001	US 1989-341094	19890420
	CA 2010425	AA	19901020	CA 1990-2010425	19900220
	JP 02292279	A2	19901203	JP 1990-102759	19900418
	US 34201	E	19930323	US 1992-868750	19920414
PRAI	US 1989-341094		19890420		

OS MARPAT 114:185242
AB Title N-aryl-N-piperidinylamides I [R = (substituted) Ph; R1 = (alkoxy) C2-6 alkyl, C2-6 alkenyl, C2-6 alkoxy; R2 = heterocyclylalkyl; R3 = H, alkoxycarbonyl, alkoxymethyl; R4 = H, Me], useful as analgesics, were prepared For example piperidinylpropanamide II was subjected to N-alkylation by BrCH2CH2OH, followed by reaction with MeSO2Cl. Subsequent reaction with clonidine hydrochloride gave title propanamide III. The ED50 of III in the mouse hot-plate analgesia test was 2 mg/kg. The ED50 of 126 other I were determined
IT **133237-12-4P 133237-34-0P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of, as analgesic)
RN 133237-12-4 CAPLUS
CN 4-Piperidinecarboxylic acid, 1-[2-[2-[(2,6-dichlorophenyl)amino]-1H-imidazol-1-yl]ethyl]-4-[(1-oxopropyl)phenylamino]-, methyl ester (9CI) (CA INDEX NAME)



RN 133237-34-0 CAPLUS
CN 4-Piperidinecarboxylic acid, 1-[2-[2-[(2,6-dichlorophenyl)amino]-4,5-dihydro-1H-imidazol-1-yl]ethyl]-4-[(1-oxopropyl)phenylamino]-, methyl ester (9CI) (CA INDEX NAME)



L12 ANSWER 13 OF 31 CAPLUS COPYRIGHT 2004 ACS on STN
AN 1991:61710 CAPLUS
DN 114:61710
TI Hypoglycemic phenylamidines and guanidines and their preparation
IN Gopalan, Balasubramanian
PA Boots, Co. PLC, UK
SO Brit. UK Pat. Appl., 75 pp.
CODEN: BAXXDU
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	GB 2226562	A1	19900704	GB 1989-29260	19891228
	GB 2226562	B2	19920708		
	IN 169912	A	19920111	IN 1989-BO1	19890102
	FI 95565	B	19951115	FI 1989-5956	19891213
	FI 95565	C	19960226		
	NO 8905023	A	19900817	NO 1989-5023	19891214
	NO 177993	B	19950925		
	NO 177993	C	19960103		
	DK 8906408	A	19900817	DK 1989-6408	19891218
	AU 8947037	A1	19901108	AU 1989-47037	19891220
	AU 632778	B2	19930114		
	CA 2006577	AA	19900702	CA 1989-2006577	19891222
	CA 2006577	C	19991221		
	CS 277609	B6	19930317	CS 1989-7433	19891227
	EP 385038	A1	19900905	EP 1989-313636	19891228
	EP 385038	B1	19930602		
	R: AT, BE, CH, DE, ES, FR, GR, IT, LI, LU, NL, SE				
	ZA 8909941	A	19910227	ZA 1989-9941	19891228
	AT 90074	E	19930615	AT 1989-313636	19891228
	US 5223498	A	19930629	US 1989-458237	19891228
	ES 2055115	T3	19940816	ES 1989-313636	19891228
	JP 02229148	A2	19900911	JP 1989-345135	19891229
	JP 2545475	B2	19961016		
	DD 294023	A5	19910919	DD 1989-336816	19891229
	SU 1826969	A3	19930707	SU 1989-4742813	19891229
	PL 161961	B1	19930831	PL 1989-295913	19891229
	PL 162960	B1	19940131	PL 1989-283074	19891229
	RO 105807	B1	19921230	RO 1989-143555	19891230
	RO 107945	B1	19940131	RO 1989-147103	19891230
	HU 58693	A2	19920330	HU 1990-8	19900102
	IL 92963	A1	19941007	IL 1990-92963	19900103
	SU 1797610	A3	19930223	SU 1990-4831862	19901203
	IN 171076	A	19920711	IN 1991-BO91	19910327
	RU 2052452	C1	19960120	RU 1992-5011043	19920227
	US 5373008	A	19941213	US 1993-9807	19930127
	LV 10619	B	19950820	LV 1993-815	19930630
	LT 3958	B	19960527	LT 1993-1646	19931221
	LT 3960	B	19960527	LT 1993-1647	19931221
	LT 3961	B	19960527	LT 1993-1648	19931221
	LV 10946	B	19960620	LV 1994-96	19940504
PRAI	IN 1989-BO1	A	19890102		
	GB 1989-3592	A	19890216		
	EP 1989-313636	A	19891228		
	US 1989-458237	A3	19891228		

OS MARPAT 114:61710

AB The title compds. [I; n = 0.1; R1,R2 = C1-3 aliphatic group optionally substituted by MeO, C3-7 cycloalkyl; or NR1R2 = (un)substituted and (un)saturated heterocyclyl optionally fused to a (benzene ring or containing 1-3 of O, S, SO, or SO2; R3 = straight or branched C1-7 alkyl, C3-7 cycloalkyl, (un)alkylated NH2; R4 = H, straight or branched C1-4 aliphatic group optionally substituted by MeO; R5 = H, (un)substituted straight or branched C1-6 aliphatic group, C3-7 cycloalkyl; or CR3NR4 = (un)substituted 1 or 2 N-containing heterocyclylidene; or NR4R5 = (un)substituted piperidinyl or pyrrolidinyl optionally containing O, S, (un)substituted NH; R6 = H, or ≥1 substituents selected from halo, (un)substituted alkyl, alkoxy, alkylthio, CF3, cyano, etc.] are prepared, e.g. by reaction of R6-substituted 2-H2NC6H4(CH2)nNR1R2 with R3CONR4R5 or a lactam on the presence of a condensing agent or reaction of R6-substituted 2-(NCNH)C6H4(CH2)nNR1R2 with NHR5R. Thus, freshly distilled POCl3 was added over 10-15 min to an ice-cooled (10°) solution of δ-valerolactam in benzene, followed by a solution of 4-(2-aminophenyl)morpholine in benzene and the resulting mixture was heated 32 h at 6° with stirring to give 4-[2-(2-piperidinylideneamino)phenyl]morpholine (II). Approx 350 I including their salts were prepared and at 0.2% agar homogenate/Kg showed 15-25% reduction of the plasma glucose level in rats injected with 800 mg glucose/4 mL/kg at 2 and 4 h. Tablets containing II were prepared

IT **131677-60-6P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of, as hypoglycemic)

RN 131677-60-6 CAPLUS

CN 1H-Imidazol-2-amine, 4,5-dihydro-N-[2-(4-morpholinyl)phenyl]-1-(2-phenylethyl)- (9CI) (CA INDEX NAME)



L12 ANSWER 14 OF 31 CAPLUS COPYRIGHT 2004 ACS on STN
AN 1989:8210 CAPLUS
DN 110:8210
TI Preparation of insecticidal 2-(nitroimino or cyanoimino)imidazolidine and -hexahydropyrimidine derivatives, process for their preparation, and their intermediates
IN Shiokawa, Kozo; Tsuboi, Shinichi; Moriie, Koichi; Shibuya, Katsuhiko
PA Nihon Tokushu Noyaku Seizo K. K., Japan
SO Jpn. Kokai Tokkyo Koho, 49 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 63156786	A2	19880629	JP 1986-301333	19861219
	JP 07084461	B4	19950913		
	EP 277317	A1	19880810	EP 1987-118054	19871207
	EP 277317	B1	19910403		
	R: BE, CH, DE, FR, GB, IT, LI, NL				
	US 4880933	A	19891114	US 1987-130376	19871208
	IL 84843	A1	19920621	IL 1987-84843	19871216
	CA 1320202	A1	19930713	CA 1987-554583	19871217
	BR 8706927	A	19880726	BR 1987-6927	19871218
	HU 47085	A2	19890130	HU 1987-5872	19871218
	HU 200753	B	19900828		
	JP 07278140	A2	19951024	JP 1994-291932	19941102
	JP 3209649	B2	20010917		
PRAI	IL 1986-77750	A	19860131		
	JP 1986-301333	A	19861219		

OS CASREACT 110:8210; MARPAT 110:8210
AB The title compds. [I; R = H, alkyl; W = 5- or 6-membered heterocyclyl containing at least 1 N, O, S; Y = O2N, cyano; A = (un)substituted (CH2)2-3; Z = (un)substituted alkyl, alkenyl, alkynyl, aryl, alkoxy, alkylthio, arylthio, or cycloalkyl, cyano, CHO, aryloxy, alkenyloxy, (un)substituted heterocyclyl containing N, O, or S, (un)substituted (thio)carbamoyl, CO2R1, etc.; R1 = Q, (un)substituted heterocyclyl containing N, O, or S; T = S, S2, (CO)2, C(S), S(O)2], useful as insecticides, were prepared 60% NaH (0.4 g) was added at room temperature to a solution of 3.2 g 1-[2-(3,5-dichloropyrid-2-yloxy)ethyl]-2-nitroiminoimidazolidine in DMF and the mixture was stirred until evolution of H ceased. Then, 1.7 g 2-chloro-5-(chloromethyl)thiazole was added at room temperature and the mixture was stirred
at room temperature for 1 h and at 40° for 30 min to give 2.7 g an imidazolidine derivative II. I at ≤200 ppm exhibited excellent insecticidal activity against Nephotettix cincticeps and Sogatella furcifera.
IT **117905-58-5P 117905-63-2P 117905-87-0P**
117905-88-1P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of, as intermediate for insecticide)
RN 117905-58-5 CAPLUS
CN 1H-Imidazol-2-amine, 4,5-dihydro-N-nitro-1-[2-(2-pyridinyl)ethyl]- (9CI) (CA INDEX NAME)



RN 117905-63-2 CAPLUS
CN 1H-Imidazol-2-amine, 1-[2-(6-chloro-2-pyridinyl)ethyl]-4,5-dihydro-N-nitro-
(9CI) (CA INDEX NAME)



RN 117905-87-0 CAPLUS
CN 1H-Imidazol-2-amine, 1-[2-(3-chlorophenyl)ethyl]-4,5-dihydro-N-nitro-
(9CI) (CA INDEX NAME)



RN 117905-88-1 CAPLUS
CN 1H-Imidazol-2-amine, 1-[2-(2-chlorophenyl)ethyl]-4,5-dihydro-N-nitro-
(9CI) (CA INDEX NAME)


N
NH—NO2
N
CH2
CH2
Cl

L12 ANSWER 15 OF 31 CAPLUS COPYRIGHT 2004 ACS on STN
AN 1988:431932 CAPLUS
DN 109:31932
TI Comparison of α1-adrenergic receptor subtypes distinguished by chlorethylclonidine and WB 4101
AU Minneman, Kenneth P.; Han, Chide; Abel, Peter W.
CS Sch. Med., Emory Univ., Atlanta, GA, 30322, USA
SO Molecular Pharmacology (1988), 33(5), 509-14
CODEN: MOPMA3; ISSN: 0026-895X
DT Journal
LA English
AB Subtypes of α1-adrenergic receptors were previously shown to be differentiated by selective inactivation with chlorethylclonidine (CEC) or by their affinities for the competitive antagonist WB 4101. Examining 8 rat tissues, the proportions of 125IBE 2254-binding sites sensitive to inactivation by CEC correlated significantly with the proportion having a low affinity for WB 4101. However, the proportion of CEC-sensitive sites was always smaller than the proportion of low affinity WB 4101 sites. Pretreatment of hippocampus and vas deferens with CEC caused a loss of all low affinity WB 4101-binding sites, leaving only high affinity sites. In a vas deferens, CEC pretreatment decreased the potency of norepinephrine in stimulating 3H-inositol phosphate accumulation but not contractile responses. In rat liver slices, CEC inactivated norepinephrine-stimulated 3H-inositol phosphate accumulation in parallel with 125IBE-binding sites. These results suggest that: (1) the CEC-sensitive and -insensitive 125IBE 2254-binding sites are equivalent to those with a low and high affinity for WB 4101, resp., and (2) the CEC-sensitive binding sites with a low affinity for WB 4101 are the α1-adrenergic receptors linked to inositol phospholipid hydrolysis.
IT **78316-65-1**
RL: BIOL (Biological study)
(α1-adrenergic receptor subtypes sensitivity to inactivation by)
RN 78316-65-1 CAPLUS
CN 1H-Imidazol-2-amine, 1-[2-chloro-2-(2,6-dichlorophenyl)ethyl]-4,5-dihydro- (9CI) (CA INDEX NAME)



L12 ANSWER 16 OF 31 CAPLUS COPYRIGHT 2004 ACS on STN
AN 1987:629897 CAPLUS
DN 107:229897
TI Heterogeneity of α1-adrenergic receptors revealed by chlorethylclonidine
AU Han, Chide; Abel, Peter W.; Minneman, Kenneth P.
CS Sch. Med., Emory Univ., Atlanta, GA, 30322, USA
SO Molecular Pharmacology (1987), 32(4), 505-10
CODEN: MOPMA3; ISSN: 0026-895X
DT Journal
LA English
AB Chlorethylclonidine (CEC) has previously been shown to inactivate only a subpopulation of the α1-adrenergic receptor binding sites in rat brain. α1-Adrenergic receptors were compared in different tissues to determine whether such selective inactivation might reveal the presence of distinct receptor subtypes. Pretreatment of broken cell prepns. with 10 μM CEC for 10 min caused a 70-80% decrease in the d. of specific 125I-labeled BE 2254 binding sites in rat liver and spleen, a 25% decrease in neocortex, but no loss in kidney, hippocampus, heart, vas deferens, or caudal artery. The effect of CEC in liver was not reversed by extensive washing, suggesting irreversible inactivation. The selectivity between different tissues was due to differences in the efficacy of CEC inactivating the binding sites and not due to differences in binding affinity. To determine whether the effects on 125I-BE 2254 binding reflected selective inactivation of functional receptors, contractile responses of rat spleen and vas deferens were examined Pretreatment of intact tissues with 100 μM CEC for 30 min caused a large decrease in the potency and maximal contraction to norepinephrine in spleen but had no effect in vas deferens. Inhibition of specific 125I-BE 2254 binding by various agonists and antagonists was determined in CEC-sensitive (liver, spleen) and insensitive (hippocampus, vas deferens) tissues. Although many drugs had similar affinities in all tissues, others were substantially less potent in the CEC-sensitive tissues. Apparently, there are at least 2 subtypes of α-adrenergic receptors with different pharmacol. properties in mammalian tissues, only 1 of which is inactivated by CEC.
IT **78316-65-1**
RL: BIOL (Biological study)
(α1-adrenergic receptor subpopulation inactivation by)
RN 78316-65-1 CAPLUS
CN 1H-Imidazol-2-amine, 1-[2-chloro-2-(2,6-dichlorophenyl)ethyl]-4,5-dihydro- (9CI) (CA INDEX NAME)



L12 ANSWER 17 OF 31 CAPLUS COPYRIGHT 2004 ACS on STN
AN 1987:169651 CAPLUS
DN 106:169651
TI Differentiation of α1-adrenergic receptors linked to phosphatidylinositol turnover and cyclic AMP accumulation in rat brain
AU Johnson, Ronald D.; Minneman, Kenneth P.
CS Sch. Med., Emory Univ., Atlanta, GA, 30322, USA
SO Molecular Pharmacology (1987), 31(3), 239-46
CODEN: MOPMA3; ISSN: 0026-895X
DT Journal
LA English
AB Activation of α1-adrenergic receptors in slices of rat brain increases inositol phosphate accumulation, increases basal cAMP [60-92-4] accumulation, and potentiates the increase in cAMP caused by adenosine [58-61-7]. These 3 responses were compared to determine whether they are mediated by the same receptors. The increase in inositol phosphates and the potentiation of cAMP accumulation in cerebral cortex were largely blocked by chelation of extracellular Ca, whereas the increase in basal cAMP was not affected. The magnitude of the increase in inositol phosphates in different brain regions correlated with the magnitude of the potentiation of cAMP accumulation, but neither of these correlated with the magnitude of the increase in basal cAMP. Although other alkylating agents inactivated all of the α1-adrenergic receptor-binding sites labeled with 125I-labeled BE 2254 [40077-13-2] in membrane prepns. of cerebral cortex, chlorethylclonidine (CEC) [**78316-65-1**] potently and selectively inactivated only half of these sites. Pretreatment with CEC partially blocked the increase in basal cAMP, but not the increase in inositol phosphates or potentiation of cAMP accumulation in slices of cerebral cortex. Comparing different brain regions, there was a better correlation between the d. of 125IBE 2254-binding sites not inactivated by CEC with the magnitude of the increase in inositol phosphates or potentiation of cAMP accumulation than with the increase in basal cAMP. Although the largest increase in inositol phosphates was observed in slices of hippocampus, there was only a small increase in basal cAMP in this region, and CEC did not inactivate any 125IBE-binding sites in hippocampus. Phentolamine and WB 4101 were more potent in inhibiting specific 125IBE 2254 binding in hippocampus than in cerebral cortex. After treatment of cerebral cortical membranes with CEC, however, these drugs had potencies similar to those observed in hippocampus. Apparently, the α1-adrenergic receptors mediating increases in basal cAMP accumulation can be differentiated from those mediating increases in inositol phosphate accumulation and potentiating adenosine stimulated cAMP accumulation by their binding properties, Ca dependency, regional distribution, and sensitivity to the alkylating agent CEC.
IT **78316-65-1**
RL: BIOL (Biological study)
(α1-adrenergic receptors of brain response to, cAMP and phosphatidylinositol metabolism in relation to)
RN 78316-65-1 CAPLUS
CN 1H-Imidazol-2-amine, 1-[2-chloro-2-(2,6-dichlorophenyl)ethyl]-4,5-dihydro- (9CI) (CA INDEX NAME)


N
NH2
N
CH2
CH
Cl
Cl
Cl

L12 ANSWER 18 OF 31 CAPLUS COPYRIGHT 2004 ACS on STN
AN 1986:497375 CAPLUS
DN 105:97375
TI Cyclic guanidines. XV. Synthesis and biological activities of (substituted phenyl)-imidazo[1,2-a]imidazole derivatives
AU Ishikawa, Fumiyoshi; Kitagawa, Masayuki; Satoh, Yoshinari; Saegusa, Junji; Tanaka, Satoru; Shibamura, Seiichi; Chiba, Tomomi
CS Res. Inst., Daiichi Seiyaku Co., Tokyo, 134, Japan
SO Chemical & Pharmaceutical Bulletin (1985), 33(7), 2838-48
CODEN: CPBTAL; ISSN: 0009-2363
DT Journal
LA English
OS CASREACT 105:97375
AB Tetrahydro-1H-imidazo[1,2-a]imidazoles I (R = H, Cl, Me, F) and their oxo derivs. II and III were prepared and evaluated for antihypertensive and diuretic activities. Antihypertensive activity in spontaneously hypertensive rats (SHR) was observed with I, whereas II and III did not possess the activity. Diuretic effects in SHR and normotensive rats were observed with I and II-III. The relationship between the activities and the substituents on the Ph ring is discussed.
IT **78316-64-0P 94523-80-5P 103866-06-4P**
103866-08-6P 103866-10-0P 103866-11-1P
103866-13-3P 103866-16-6P 103866-18-8P
103866-20-2P 103866-22-4P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and chlorination-cyclization of)
RN 78316-64-0 CAPLUS
CN 1H-Imidazole-1-ethanol, 2-amino-α-(2,6-dichlorophenyl)-4,5-dihydro-, monohydrobromide (9CI) (CA INDEX NAME)



● HBr

RN 94523-80-5 CAPLUS
CN 1H-Imidazole-1-ethanol, 2-amino-4,5-dihydro-α-phenyl-, monohydrobromide (9CI) (CA INDEX NAME)



● HBr

RN 103866-06-4 CAPLUS
CN 1H-Imidazole-1-ethanol, 2-amino-α-(2-chlorophenyl)-4,5-dihydro-, monohydrobromide (9CI) (CA INDEX NAME)



● HBr

RN 103866-08-6 CAPLUS
CN 1H-Imidazole-1-ethanol, 2-amino-α-(3-chlorophenyl)-4,5-dihydro-, monohydrobromide (9CI) (CA INDEX NAME)



● HBr

RN 103866-10-0 CAPLUS
CN 1H-Imidazole-1-ethanol, 2-amino-α-(4-chlorophenyl)-4,5-dihydro-, monohydrobromide (9CI) (CA INDEX NAME)



● HBr

RN 103866-11-1 CAPLUS
CN 1H-Imidazole-1-ethanol, 2-amino-4,5-dihydro-α-(4-methylphenyl)-, monohydrobromide (9CI) (CA INDEX NAME)



● HBr

RN 103866-13-3 CAPLUS
CN 1H-Imidazole-1-ethanol, 2-amino-α-(3,4-dichlorophenyl)-4,5-dihydro-, monohydrobromide (9CI) (CA INDEX NAME)



● HBr

RN 103866-16-6 CAPLUS
CN 1H-Imidazole-1-ethanol, 2-amino-α-(2-chloro-6-fluorophenyl)-4,5-dihydro-, monohydrobromide (9CI) (CA INDEX NAME)



● HBr

RN 103866-18-8 CAPLUS
CN 1H-Imidazole-1-ethanol, 2-amino-α-(2,6-difluorophenyl)-4,5-dihydro-, monohydrobromide (9CI) (CA INDEX NAME)



● HBr

RN 103866-20-2 CAPLUS
CN 1H-Imidazole-1-ethanol, 2-amino-α-(2-chloro-6-methylphenyl)-4,5-dihydro-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 103866-22-4 CAPLUS
CN 1H-Imidazole-1-ethanol, 2-amino-α-(2,6-dimethylphenyl)-4,5-dihydro-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

L12 ANSWER 19 OF 31 CAPLUS COPYRIGHT 2004 ACS on STN
AN 1986:50874 CAPLUS
DN 104:50874
TI N-(4-Piperidinyl) bicyclic condensed 2-imidazolamine derivatives
IN Janssens, Frans Eduard; Torremans, Joseph Leo Ghislanus; Hens, Jozef Francis; Van Offenwert, Theophilus Theresia Joannes
PA Janssen Pharmaceutica N. V., Belg.
SO Eur. Pat. Appl., 68 pp.
CODEN: EPXXDW
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 151824	A2	19850821	EP 1984-201812	19841206
	EP 151824	A3	19851009		
	EP 151824	B1	19900404		
	R: AT, BE, CH, DE, FR, GB, IT, LI, LU, NL, SE				
	US 4588722	A	19860513	US 1984-660670	19841015
	CA 1246070	A1	19881206	CA 1984-469245	19841204
	AT 51621	E	19900415	AT 1984-201812	19841206
	ES 539266	A1	19860116	ES 1984-539266	19841231
	AU 8537363	A1	19850801	AU 1985-37363	19850107
	AU 575612	B2	19880804		
	JP 60174778	A2	19850909	JP 1985-251	19850107
	RO 91075	B3	19870227	RO 1985-117231	19850107
	PL 144514	B1	19880630	PL 1985-251476	19850107
	FI 8500078	A	19850710	FI 1985-78	19850108
	FI 83781	B	19910515		
	FI 83781	C	19910826		
	NO 8500084	A	19850710	NO 1985-84	19850108
	DK 8500088	A	19850710	DK 1985-88	19850108
	HU 37780	A2	19860228	HU 1985-62	19850108
	HU 196389	B	19881128		
	ZA 8500186	A	19860827	ZA 1985-186	19850108
	IL 74017	A1	19880331	IL 1985-74017	19850108
	SU 1400509	A3	19880530	SU 1985-3838812	19851008
	NO 8902563	A	19850710	NO 1989-2563	19890621
PRAI	US 1984-569115		19840109		
	US 1984-660670		19841015		
	EP 1984-201812		19841206		
	NO 1985-84		19850108		

OS CASREACT 104:50874
AB The title compds. [I; A = (un)substituted C6H6 or pyridine ring; R = H, alkyl; R1 = H, alkyl, cycloalkyl, aralkyl, (alkyl)furanyl, (alkyl)imidazolyl, (halo)thienyl, pyridinyl, pyrazinyl, thiazolyl, (un)substituted Ph; R2 = H, alkyl, cycloalkyl, aralkyl, alkanoyl, alkoxycarbonyl; R3 = R4Z, (un)substituted saturated heterocyclyl; R4 = acyl, acylamino, acyloxy, acylthio, (un)substituted Ph, aryl, etc.; Z = alkylene] were prepared Thus 3-chloro-2-nitropyridine was aminolyzed with 4-FC6H4CH2NH2 and the product hydrogenated to give N3-[(4-fluorophenyl)methyl]-2,3-pyridinediamine. This was condensed with Et 4-isothiocyanatopiperidinecarboxylate to give pyridinylthiourea derivative II which was cyclized by heating in EtOH with HgO and S to give imidazopyridinamine III (R5 = CO2Et). The latter was decarboxylated by heating in 48% aqueous HBr to give III.2HBr (R5 = H) which was alkylated with a p-methoxyphenethyl halide to give III (R5 = 4-MeOC6H4CH2CH2) (IV). I are antihistaminics. In mice IV inhibited compound 48/80-induced lethality

with an ED50 of 0.08 mg/kg s.c. or orally.

IT **99780-57-1P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of, as antihistaminic)

RN 99780-57-1 CAPLUS

CN 1H-Benzimidazol-2-amine, N-[1-[2-(2-amino-1H-imidazol-1-yl)ethyl]-4-piperidinyl]-1-[(4-fluorophenyl)methyl]- (9CI) (CA INDEX NAME)



L12 ANSWER 20 OF 31 CAPLUS COPYRIGHT 2004 ACS on STN
AN 1981:443112 CAPLUS
DN 95:43112
TI 2-Aryl-imidazo[1,2-a]imidazole derivatives
PA Daiichi Seiyaku Co., Ltd., Japan
SO Jpn. Kokai Tokkyo Koho, 5 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 56008385	A2	19810128	JP 1979-84555	19790704
	JP 63006069	B4	19880208		
PRAI	JP 1979-84555		19790704		

OS CASREACT 95:43112
AB Fifteen title derivs. I (R, R1 = H, halo, alkyl) were prepared by cyclization of II (R2 = halo) and tested as hypotensives and diuretics in rats (data given). Thus, stirring 14.2 g II.HBr (R = 2-Cl, R1 = 6-Cl, R2 = OH) with SOCl2 3 h at room temperature, concentration, and refluxing the residue with
20 g KOH in aqueous MeOH 5 h gave 5.8 g I (R = 2-Cl, R1 = 6-Cl), which was converted to the HCl salt.
IT **78316-64-0**
RL: RCT (Reactant); RACT (Reactant or reagent)
(chlorination of, by thionyl chloride)
RN 78316-64-0 CAPLUS
CN 1H-Imidazole-1-ethanol, 2-amino-α-(2,6-dichlorophenyl)-4,5-dihydro-, monohydrobromide (9CI) (CA INDEX NAME)



● HBr

IT **78316-65-1P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and cyclization of, imidazoimidazole derivative from)
RN 78316-65-1 CAPLUS
CN 1H-Imidazol-2-amine, 1-[2-chloro-2-(2,6-dichlorophenyl)ethyl]-4,5-dihydro- (9CI) (CA INDEX NAME)


N
NH2
N
CH2
CH
Cl
Cl
Cl

L12 ANSWER 22 OF 31 CAPLUS COPYRIGHT 2004 ACS on STN
AN 1974:120953 CAPLUS
DN 80:120953
TI Antihypertensive 2-amino-4-(halophenyl)imidazoline salts
IN Kummer, Werner; Koeppe, Herbert; Staehle, Helmut; Haarmann, Walter
PA Boehringer, C. H., Sohn
SO Ger. Offen., 16 pp.
CODEN: GWXXBX
DT Patent
LA German
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	DE 2235328	A1	19740207	DE 1972-2235328	19720719
	ES 417006	A1	19760301	ES 1973-417006	19730717
	JP 49051279	A2	19740518	JP 1973-82434	19730718
	FR 2192841	A1	19740215	FR 1973-26601	19730719
	GB 1444593	A	19760804	GB 1973-34436	19730719
	ES 430752	A1	19761016	ES 1974-430752	19741007
	US 4073905	A	19780214	US 1977-775736	19770309
PRAI	DE 1972-2235314		19720719		
	DE 1972-2235328		19720719		
	US 1973-379750		19730716		

AB Seventeen imidazolines (I; Rn = 4-Cl, 2,4- or 2,6-Cl2; R1 = Me, Et, CH2CH2OH, CH2CH2NEt2, furfuryl, 2-morpholinoethyl; Z = NHR2 with R2 = H, Me, Et, CH2CH2NEt2, furfuryl, 2-pyrrolidin-1-ylethyl) useful as antihypertensives, antiarrhythmics, and blood platelet aggregation inhibitors, were prepared as salts by reaction of I (Z = SMe) with R2NH2, by alkylation of I (Z = NH2) or by reaction of RnC6H5-n-CH(NHR1)CH2NH2 with BrCN or with MeSC(:NR3)NHR2 (R3 = H, Me) and subsequent cyclization.

IT **52157-31-0P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 52157-31-0 CAPLUS
CN 1H-Imidazol-2-amine, 5-(2,6-dichlorophenyl)-4,5-dihydro-1-[2-(4-morpholinyl)ethyl]-, ethanedioate (1:2) (9CI) (CA INDEX NAME)

CM 1

CRN 52157-30-9
CMF C15 H20 Cl2 N4 O



CM 2

CRN 144-62-7
CMF C2 H2 O4



L12 ANSWER 23 OF 31 CAPLUS COPYRIGHT 2004 ACS on STN
AN 1973:449091 CAPLUS
DN 79:49091
TI Amidines. 4. Synthesis of tricyclic guanidines related to 1,2,3,5-tetrahydroimidazo[2,1-b]quinazoline, a new antihypertensive agent
AU Jen, Timothy; Bender, Paul; Van Hoeven, Helen; Dienel, Barbara; Loev, Bernard
CS Res. Dev. Div., Smith Kline and French Lab., Philadelphia, PA, USA
SO Journal of Medicinal Chemistry (1973), 16(4), 407-11
CODEN: JMCMAR; ISSN: 0022-2623
DT Journal
LA English
AB 1,2,3,5-Tetrahydroimidazo[2,1-b]quinazoline-HCl (I-HCl) [33376-05-5], 1,2,3,4-tetrahydro-6H-pyrimido[2,1-b]quinazoline-HBr (II-HBr) [41363-26-2], and 2,3-dihydro-1H-imidazo[1,2-a]benzimidazole-HCl (III-HCl) [41363-27-3] showed antihypertensive activity at 2.5, 2, and 10 mg/kg orally, resp., in neurogenic hypertensive dogs. In metacorticoid hypertensive rats, II was less potent than I in lowering systolic pressure.
IT **41921-60-2P 41921-61-3P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 41921-60-2 CAPLUS
CN 1H-Imidazol-2-amine, 4,5-dihydro-1-[2-(2-nitrophenyl)ethyl]-, monohydrobromide (9CI) (CA INDEX NAME)



● HBr

RN 41921-61-3 CAPLUS
CN 1H-Imidazol-2-amine, 1-[2-(2-aminophenyl)ethyl]-4,5-dihydro-, monohydrobromide (9CI) (CA INDEX NAME)



● HBr

L12 ANSWER 24 OF 31 CAPLUS COPYRIGHT 2004 ACS on STN
AN 1972:25174 CAPLUS
DN 76:25174
TI Imidazoles. LXV. Synthesis of 2-aminoimidazole derivatives based on 2-haloimidazoles
AU Priimenko, B. A.; Kochergin, P. M.
CS Zaporozh. Gos. Med. Inst., Zaporozhe, USSR
SO Khimiya Geterotsiklicheskikh Soedinenii (1971), 7(9), 1248-51
CODEN: KGSSAQ; ISSN: 0132-6244
DT Journal
LA Russian
AB 1-Alkyl(or hydroxyalkyl) - 2 - bromo - 4,5 - diphenylimidazoles undergo nucleophilic substitution with NH3, alkyl-, or arylamines either in an autoclave or in DMF to give 31 corresponding 2-aminoimidazoles in yields of 44-92%.
IT **34654-32-5P 34654-46-1P 34654-48-3P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 34654-32-5 CAPLUS
CN 1H-Imidazole-1-ethanol, α,4,5-triphenyl-2-(phenylamino)- (9CI) (CA INDEX NAME)



RN 34654-46-1 CAPLUS
CN 1H-Imidazole-1-ethanol, 2-[(4-methylphenyl)amino]-α,4,5-triphenyl- (9CI) (CA INDEX NAME)



RN 34654-48-3 CAPLUS
CN 1H-Imidazole-1-ethanol, 2-[(4-methoxyphenyl)amino]-α,4,5-triphenyl- (9CI) (CA INDEX NAME)


Ph
CH2
CH
OH
Ph
N
NH
N
Ph
OMe

L12 ANSWER 25 OF 31 CAPLUS COPYRIGHT 2004 ACS on STN
AN 1968:59499 CAPLUS
DN 68:59499
TI New synthesis of the glycocyamidine group
AU Melandri, Max M.; Buttini, Annibale; Gallo, Gian G.; Pasqualucci, Carmine R.
CS Soc. Ital. Prod. Schering, Milan, Italy
SO Annali di Chimica (Rome, Italy) (1966), 56(10), 1259-66
CODEN: ANCRAI; ISSN: 0003-4592
DT Journal
LA Italian
AB To 1 mole guanidine and 5 moles NaOH in 1.2 l. acetone, 1.2 moles CHCl3 was added dropwise, the mixture refluxed 2 hrs., stripped of acetone, dissolved in H2O, acidified, cooled with ice, filtered, the cake dissolved in base and re-precipitated to give 27% I (R = OH), m. 285-7°; HCl salt m. 219°, acid chloride (II) m. 264-6°. The structure of I was established by uv, ir and N.M.R. spectra. II was converted to the following I derivs.: (R, m.p., and % yield given): OMe, 205-7°, -; OEt, 194-5°, 80; OC2H4Ph, 196-7°, -; OC2H4NEt2, 178-80°, -; NHC2H4NEt2, 182-3°, 65; NHC3H6NEt2, 172-3°, -; NHC2H4NMe2, 184-5°, -.
IT **17050-07-6P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 17050-07-6 CAPLUS
CN 4-Imidazolidinone, 2-imino-3-(2-morpholinoethyl)-5,5-diphenyl- (6CI, 8CI) (CA INDEX NAME)





L12 ANSWER 26 OF 31 CAPLUS COPYRIGHT 2004 ACS on STN
AN 1964:404209 CAPLUS
DN 61:4209
OREF 61:651h,652a-f
TI 1-Phenethyl-2-iminoimidazolidines, a new class of compounds with ganglion-regulating activity
AU Wollweber, H.; Hiltmann, R.; Stoepel, K.; Kroneberg, G.
CS Farbenfabriken Bayer A.-G., Wuppertal-Elberfeld, Germany
SO Med. Chem., Abhandl. Med. Chem. Forschungsstaetten Farbwerke Hoechst A.G. (1963), 7, 248-61
DT Journal
LA Unavailable
AB To a solution of the Grignard reagent from 225 g. 3-Br-C6H4CF3, 26 g. Mg, and 500 ml. Et2O was added dropwise a solution of 44 g. ethylene oxide in 200 ml. Et2O to give after hydrolysis with aqueous NH4Cl 74.9 g. 3-F3CC6H4CH2CH2OH (I), b12 102-6°. I (38 g.) was saturated at 100° with dry HBr to give 45 g. 3-F3CC6H4CH2CH2Br (II), b12 92-4°. A mixture of 45 g. II and 50 g. (CH2NH2)2 was refluxed overnight, distilled in vacuo, the residue basified, and the oil separated to give 19.4 g. 3-F3CC6H4CH2CH2-NHC2H4NH2, b0.15 96-8°. A mixture of 80 g. PhCH2CH2Cl and 160 g. H2NCH2CH2NHCO2Et was refluxed 8 hrs. to give 62 g. PhCH2CH2NHCH2CH2NHCO2Et (III), b0.05 140°. III (53 g.) in 500 ml. Et2O was reduced with LiAlH4 to give 16.1 g. PhCH2CH2NHCH2CH2NHMe, b12 84-6°. A mixture of 55 g. PhCH2CH2NHCH2CH2NH2 (IV), 47 g. S-methylisothiuronium sulfate, 200 ml. EtOH. and 40 ml. water was refluxed 2 hrs. to give 80 g. 2PhCH2CH2NHCH2CH2NHC(:NH)NH2.H2SO4 (V), m. 188° (decomposition) (EtOH-AcOEt). V (60 g.) was heated 1.5 hrs. at 150-60, 200 ml. amyl alc. added, and the mixture refluxed 6 hrs. to give 28 g. VI (R1 = R2 = R3 = R4 = R5 = R6 = R7 = H, m = n = 1, X = NH) (VII).0.5 H2SO4, m. 206.5-7.5°. A solution of 10.6 g. BrCN in 50 ml. benzene was added dropwise at 20-30° to a solution of 18 g. IV in 100 ml. benzene and the mixture stirred 1 hr. to give VII HBr salt, m. 144-6° (AcOEt). PhCH2CH2NHCH2CH2OH with concentrated HBr at 170° gave PhCH2CH2NHCH2CH2Br HBr salt, m. 173-5°; this (15.5 g.) in 45 ml. water treated with a solution of 4.05 g. KOCN in 10 ml. water gave an oil which slowly dissolved upon vigorous shaking. After 0.5 hr. the solution was treated with K2CO3 and the oil extracted with CH2Cl2 to give 8.5 g. X = O analog of VII, b0.25 122-5°; HCl salt m. 178-9°. Similarly prepared were VI (R1, R1, R1, R1, R1, R2, R2, n, m, m, m.p. HBr salt, and b.p./mm. of diamine corresponding to IV given): H, H, OMe, H, H, H, H, 1, 1, NH, 166-7°, 140°/0.1; H, OMe, H, H, H, H, H, 1, 1, NH, 139°, 124°/0.1; H, (R2R3 =) CH2O2, H, H, H, H, 1, 1, NH, 217°, 130°/0.2; H, H, Me, H, H, H, H, 1, 1, NH, 193-5°, 100°/0.2; H, Me, H, H, H, H, H, 1, 1, NH, 148-9°, 116°/0.5; Me, H, H, H, H, H, H, 1, 1, NH, 173-5°, 118°/0.2; H, H, Cl, H, H, H, H, 1, 1, NH, 187°, 112°/0.1; H, Cl, H, H, H, H, H, 1, 1, NH, 138°, 110°/0.05; H, H, H, H, H, H, H, 1, 1, NMe, 180°, 85°/12; H, H, H, H, H, H, Me, 1, 1, NH, 186-7°, 90°/0.1; H, H, H, H, H, Me, H, 1, 1, NH, 111-13°, 80°/0.1; H, OMe, H, H, Me, Me, H, 1, 1, NH, 156°, 125°/0.05; H, H, H, OH, H, H, H, 1, 1, NH, 173°, 164°/0.05; H, H, H, H, H, H, H, 1, 0, NH, 202-3°, 84°/0.2; Cl, H, H, H, H, H, H, 1, 0, NH, 270-3° (decomposition) (1/2H2SO4 salt), 102°/0.1. Also prepared were VIII (R1, R2, m.p. HBr salt, and b.p./mm. diamine given): H, H, 153°, 100°/0.1; H, Me, 140°, 125°/12; Me, H, 115-17°, 126°/12.
Similarly prepared from α-phenyl-ethylenediamine, b0.3 84°, was

4-phenyl-2-iminoimidazolidine HBr salt, m. 177°. Toxicity and pharmacol. data are given for all compds.

IT **94523-80-5**, 1-Imidazolidineethanol, 2-imino-α-phenyl-, hydrobromide **94882-14-1**, Imidazolidine, 1-(p-chlorophenethyl)-2-imino-, hydrobromide **94934-39-1**, Imidazolidine, 1-(m-chlorophenethyl)-2-imino-, hydrobromide **96197-87-4**, Imidazolidine, 2-imino-1-(o-methylphenethyl)-, hydrobromide **96197-88-5**, Imidazolidine, 2-imino-1-(p-methylphenethyl)-, hydrobromide **96197-90-9**, Imidazolidine, 2-imino-5-methyl-1-phenethyl-, hydrobromide **96197-96-5**, Imidazolidine, 2-imino-1-(p-methoxyphenethyl)-, hydrobromide **96433-97-5**, Imidazolidine, 2-imino-1-(m-methylphenethyl)-, hydrobromide **96434-01-4**, Imidazolidine, 2-imino-1-(m-methoxyphenethyl)-, hydrobromide **96651-72-8**, Imidazolidine, 2-imino-1-[3,4-(methylenedioxy)phenethyl]-, hydrobromide
(preparation of)

RN 94523-80-5 CAPLUS

CN 1H-Imidazole-1-ethanol, 2-amino-4,5-dihydro-α-phenyl-, monohydrobromide (9CI) (CA INDEX NAME)



● HBr

RN 94882-14-1 CAPLUS

CN Imidazolidine, 1-(p-chlorophenethyl)-2-imino-, hydrobromide (7CI) (CA INDEX NAME)



● HBr

RN 94934-39-1 CAPLUS
CN Imidazolidine, 1-(m-chlorophenethyl)-2-imino-, hydrobromide (7CI) (CA INDEX NAME)



● HBr

RN 96197-87-4 CAPLUS
CN Imidazolidine, 2-imino-1-(o-methylphenethyl)-, hydrobromide (7CI) (CA INDEX NAME)



● HBr

RN 96197-88-5 CAPLUS
CN Imidazolidine, 2-imino-1-(p-methylphenethyl)-, hydrobromide (7CI) (CA INDEX NAME)



● HBr

RN 96197-90-9 CAPLUS
CN Imidazolidine, 2-imino-5-methyl-1-phenethyl-, hydrobromide (7CI) (CA INDEX NAME)



● HBr

RN 96197-96-5 CAPLUS
CN Imidazolidine, 2-imino-1-(p-methoxyphenethyl)-, hydrobromide (7CI) (CA INDEX NAME)



● HBr

RN 96433-97-5 CAPLUS
CN Imidazolidine, 2-imino-1-(m-methylphenethyl)-, hydrobromide (7CI) (CA INDEX NAME)



● HBr

RN 96434-01-4 CAPLUS
CN Imidazolidine, 2-imino-1-(m-methoxyphenethyl)-, hydrobromide (7CI) (CA INDEX NAME)



● HBr

RN 96651-72-8 CAPLUS
CN Imidazolidine, 2-imino-1-[3,4-(methylenedioxy)phenethyl]-, hydrobromide (7CI) (CA INDEX NAME)



● HBr

L12 ANSWER 27 OF 31 CAPLUS COPYRIGHT 2004 ACS on STN
AN 1964:63736 CAPLUS
DN 60:63736
OREF 60:11246d-f
TI Pharmacology of a new substance with ganglion-stimulating activity
AU Kroneberg, Guenther; Stoepel, Kurt
SO Med. Chem., Abhandl. Med.-Chem. Forschungsstaetten Farbenfabriken Bayer A.G. (1963), 7, 215-47
DT Journal
LA Unavailable
AB The pharmacology of 1-(β-phenylethyl)-2-iminoimidazoline sulfate (I) has been studied. Low doses of I raise the blood pressure of cats and cause contractions of the nictitating membrane. The latter effect is strongly marked on injection in the carotid artery. Sympathicolytics reduce the efficiency on blood pressure; cocaine weakly intensifies. The effect on blood pressure and nictitating membrane is weakened after hexamethonium; 50% of the hypertensive effect is accounted for by the secretion of catechol amines from the adrenals. Further low interaction of I takes place on the peripheral side of the ganglion. Repeated injections of large doses of I produced tachyphylaxia. Fast intravenous injections give derangements of rhythms of the heart which remain unchanged on vagotomy and which are annulled by atropine. Slow intravenous injections raise blood pressure. Doses of I which just raise the blood pressure do not change the motility of the gut; higher doses stimulate the gut. No method of administration produces a useful lasting rise of blood pressure. The results are discussed in regard to mechanism of the activity of nicotine and acetylcholine and the constitution and efficiency of substances with nicotinic and antinicotine activity.
IT **94523-85-0**, Imidazolidine, 2-imino-1-phenethyl-, sulfate (pharmacology of)
RN 94523-85-0 CAPLUS
CN Imidazolidine, 2-imino-1-phenethyl-, sulfate (7CI) (CA INDEX NAME)

CM 1

CRN 72105-70-5
CMF C11 H15 N3



CM 2

CRN 7664-93-9
CMF H2 O4 S



L12 ANSWER 28 OF 31 CAPLUS COPYRIGHT 2004 ACS on STN
AN 1962:475998 CAPLUS
DN 57:75998
OREF 57:15121h-i
TI 1-Cyclohexyl-5-(1-hydroxyalkyl)tetrazoles
IN Ugi, Ivar; Meyr, Rudolf
SO 2 pp.
DT Patent
LA Unavailable

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 1131692		19620620	DE	19600109

AB The title compds. had pharmacol. and other technical uses. Cyclohexyl isocyanide (2.725 g.) and 2.25 ml. 30% aqueous CH2O in 20 ml. tetrahydrofuran treated with 15 ml. 8% H3N in C6H6, the mixture kept 4 days at room temperature and evaporated in vacuo at 20° gave 3.56 g. 1-cyclohexyl-5-(hydroxymethyl)tetrazole, m. 26-30°. Similarly were prepared the following 1-cyclohexyltetrazoles 5-substituted with the C(OH)RR' group (R, R', % yield, and m.p. given): CCl3, H (I), 63, 167-70° (C6H6); iso-Pr H, 84, 90-2°; Me, Me, 60, 103-5°; Ph, H, 41, 143-5°. Modified conditions gave 72% I, m. 170-1° (C6H6).

IT **1692-98-4**, Imidazolidine, 2-imino-1-[m-(trifluoromethyl)phenethyl]-, hydrobromide
(preparation of)

RN 1692-98-4 CAPLUS
CN Imidazolidine, 2-imino-1-[m-(trifluoromethyl)phenethyl]-, hydrobromide (7CI, 8CI) (CA INDEX NAME)



● HBr

L12 ANSWER 29 OF 31 CAPLUS COPYRIGHT 2004 ACS on STN
AN 1962:475997 CAPLUS
DN 57:75997
OREF 57:15121e-h
TI 2-Iminoimidazolidines
IN Wollweber, Hartmund; Hiltmann, Rudolf; Kroneberg, Hans G.; Stoepel, Kurt
PA Farbenfabriken Bayer A.-G.
SO 11 pp.
DT Patent
LA Unavailable

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI BE 613662		19620808	BE	
PRAI DE		19610210		

AB I can increase arterial pressure and can be used in the treatment of hypertonia. NCBr (10.6 g.) is dissolved in 100 ml. C6H6 and the solution added to 18 g. H2NCH2CH2NHCH2CH2Ph in 100 ml. C6H6 dropwise between 20 and 30° to give 26 g. I.HBr [R = R' = H, R' = CH2CH2Ph, Z = (CH2)2], m. 145-0° (alc. EtOAc). Similarly prepared are the following I.HBr (R' R', R'' Z, and m.p. given): Me, H, CH2CH2Ph, (CH2)3 180°; H, H, p-MeOC6H4CH2CH2, (CH2)2, 166-7°; H,H, CH2CH2Ph, CHMeCH2, 186-7°; H, H, CH2CH2Ph, (CH2)3, 163°; H, H, CH2CH2Ph, (CH2)2, - H2SO4 salt m. 207-8°); H, H, 3,4-(HOCH2)2C6H3CH2CH2, CH2)2, 217°; H, H, 3-MeOC6H4CH2CMe2, (CH2)2, 156°; H, H, 3-MeOC6H4CH2CH2, (CH2)2, 139°; H, H, 4-ClC6H4CH2CH2, (CH2)2, 187°; H, H, 2-MeOC4H4CH2CH2, (CH2)2, 139°; H, H, 3-ClC6H4CH2CH2, (CH2)2, 138°; H, H, Ph2CHCH2, (CH2)2, 211°; H, H, 1-methyl-2-cyclohexylethyl, (CH2)2, 115-17°; H, H, 2-cyclohexylethyl, (CH2)2, 153°; H, H, PhCH2CHMe, (CH2)2, 111-13°; H, H, 3-F3CC6H4CH2CH2, (CH2)2, 169-70°.

IT **1692-98-4**, Imidazolidine, 2-imino-1-[m-(trifluoromethyl)phenethyl]-, hydrobromide **94523-85-0**, Imidazolidine, 2-imino-1-phenethyl-, sulfate **94934-39-1**, Imidazolidine, 1-(m-chlorophenethyl)-2-imino-, hydrobromide **96197-90-9**, Imidazolidine, 2-imino-5-methyl-1-phenethyl-, hydrobromide **96197-95-4**, Imidazolidine, 2-imino-1-(o-methoxyphenethyl)-, hydrobromide **96197-96-5**, Imidazolidine, 2-imino-1-(p-methoxyphenethyl)-, hydrobromide **96434-01-4**, Imidazolidine, 2-imino-1-(m-methoxyphenethyl)-, hydrobromide **96651-72-8**, Imidazolidine, 2-imino-1-[3,4-(methylenedioxy)phenethyl]-, hydrobromide
(preparation of)

RN 1692-98-4 CAPLUS
CN Imidazolidine, 2-imino-1-[m-(trifluoromethyl)phenethyl]-, hydrobromide (7CI, 8CI) (CA INDEX NAME)



● HBr

RN 94523-85-0 CAPLUS
CN Imidazolidine, 2-imino-1-phenethyl-, sulfate (7CI) (CA INDEX NAME)

CM 1

CRN 72105-70-5
CMF C11 H15 N3



CM 2

CRN 7664-93-9
CMF H2 O4 S



RN 94934-39-1 CAPLUS
CN Imidazolidine, 1-(m-chlorophenethyl)-2-imino-, hydrobromide (7CI) (CA INDEX NAME)



● HBr

RN 96197-90-9 CAPLUS
CN Imidazolidine, 2-imino-5-methyl-1-phenethyl-, hydrobromide (7CI) (CA INDEX NAME)



● HBr

RN 96197-95-4 CAPLUS
CN Imidazolidine, 2-imino-1-(o-methoxyphenethyl)-, hydrobromide (7CI) (CA INDEX NAME)



● HBr

RN 96197-96-5 CAPLUS
CN Imidazolidine, 2-imino-1-(p-methoxyphenethyl)-, hydrobromide (7CI) (CA INDEX NAME)



● HBr

RN 96434-01-4 CAPLUS
CN Imidazolidine, 2-imino-1-(m-methoxyphenethyl)-, hydrobromide (7CI) (CA INDEX NAME)



● HBr

RN 96651-72-8 CAPLUS
CN Imidazolidine, 2-imino-1-[3,4-(methylenedioxy)phenethyl]-, hydrobromide (7CI) (CA INDEX NAME)



● HBr

L12 ANSWER 30 OF 31 CAPLUS COPYRIGHT 2004 ACS on STN
AN 1960:86466 CAPLUS
DN 54:86466
OREF 54:16445i,16446a-d
TI Hydantoins, thiohydantoins, glycocyamidines. II. Synthesis of some 3(dialkylaminoalkyl)-5,5-diphenylglycocyamidines
AU Lempert, Karoly; Breuer, Judit; Lempert-Sreter, Magda; Pataky, Istvan; Pfeifer, Klara
CS Univ. Med. Budapest, Hung.
SO Magyar Kemiai Folyoirat (1959), 65, 110-13
CODEN: MGKFA3; ISSN: 0025-0155
DT Journal
LA Unavailable
AB A method was worked out to prepare 3-dialkylaminoalkyl-5,5-diphenylglycocyamidines. The preparation was based on the NH4+-catalyzed ammonolysis of the appropriate 1-dialkylaminoalkyl-2-methylthio-2-imidazolin-5-ones. 3-(β-Diethylaminoethyl)-5,5-diphenylglycocyamidine (I), m. 161-2°, was prepared by heating 1.91 g. 1-(β-diethylaminoethyl)-2-methylthio-4,4-diphenyl-2-imidazolin-5-one (II), 0.77 g. AcONH4, and 15 ml. absolute alc. containing 0.7 g. NH3 in a bomb tube for 8 hrs. at 100-10°. After cooling, I crystallized in 55% yield. I prevents Tetracorcaused (80 mg./kg.) cramps in rats and strongly decreases the normal body temperature 3-(β-Morpholinoethyl)-5,5-diphenylglycocyamidine (III), m. 194-5°, is obtained in 28% yield by heating 3.95 g. 1-(β-morpholinoethyl)-2-methylthio-4,4-diphenyl-2-imidazoline-5-one (IV) with 45 ml. absolute alc. containing 2.8 g. NH3 for 18 hrs. at 150°. III prevents cramps caused by Tetracor and decreases body temperature less strongly than I. Both I and III were ineffectual in preventing the effects of electro shock. 3-(γ-Diethylaminopropyl)-5,5-diphenylglycocyamidine (V), m. 154-6°, was obtained by heating 3.95 g. 1-(γ-diethylaminopropyl)-2-methylthio-4,4-diphenyl-2-imidazolin-5-one (VI) with 1.54 g. AcONH4, and 33 ml. absolute alc. containing 1.4 g. NH3 for 90 min. at 100°, after which the alc. was distilled The residue was extracted with 38 ml. 2N HCl. The base (V) was liberated by dilute NH4OH and was crystallized from ether to yield 0.9 g. I, III, and V are white crystalline powders. II, IV, and VI were prepared according to Carrington and Waring (CA 44, 7776d). 1-(γ-Chloropropyl)-2-methylthio-4,4-diphenyl-2-imidazolin-5-one (VII), m. 117-22°, was prepared by boiling 2.82 g. 2-methylthio-4,4-diphenyl-2-imidazolin-5-one, 1.38 g. anhydrous K2CO3, 1.97 g. trimethylene chlorobromide, 10 ml. water, and 30 ml. MeOH for 4 hrs. VII was obtained as a yellow oil which crystallized from water in 51% yield. 1-(γ-Morpholinopropyl)-2-methylthio-4,4-diphenyl-2-imidazolin-5-one (VIII) m. 98-100°, was obtained by boiling 4.9 g. VII, 3.2 g. morpholine, 0.3 g. KI, and 75 ml. MeCOEt for 9 hrs. After cooling and filtering, the filtrate contained VIII (yield 44.5%).
IT **17050-07-6**, 4-Imidazolidinone, 2-imino-3-(2-morpholinoethyl)-5,5-diphenyl- **111162-00-6**, 4-Imidazolidinone, 2-imino-3-(2-morpholinoethyl)-5,5-diphenyl-, dihydrochloride
(preparation of)
RN 17050-07-6 CAPLUS
CN 4-Imidazolidinone, 2-imino-3-(2-morpholinoethyl)-5,5-diphenyl- (6CI, 8CI) (CA INDEX NAME)



RN 111162-00-6 CAPLUS
CN 4-Imidazolidinone, 2-imino-3-(2-morpholinoethyl)-5,5-diphenyl-, dihydrochloride (6CI) (CA INDEX NAME)



●2 HCl

L12 ANSWER 31 OF 31 CAPLUS COPYRIGHT 2004 ACS on STN
AN 1960:74608 CAPLUS
DN 54:74608
OREF 54:14234h-i,14235a
TI Orientation in the condensation of benzil with monosubstituted guanidines
AU Lampert, K.; Lempert-Sreter, Magda
CS Eovos-Lorand-Univ., Budapest, Hung.
SO Experientia (1959), 15, 412-13
CODEN: EXPEAM; ISSN: 0014-4754
DT Journal
LA German
AB An alc. solution of benzil (I) and N-benzylguanidine (II) was heated with 50 mole-% KOH to give 60-70% 2-benzylimino-4,4-diphenylimidazolidin-5-one (III), m. 240-1°. Similarly, I and N-(β-morpholimoethyl)guanidine (IV) gave 60-70% 2-(β-morpholinoethylimino)-4,4-diphenylimidazolidin-5-one (V), m. 194-5°. In the presence of 10% KOH I and II gave 20% III and 45% 3-benzyl-5,5-diphenylglycocyamidine (VI), m. 164-6°. Similarly, I and IV gave 60% 3-(β-morpholinoethyl)-5,5-diphenylglycocyamidine, m. 198-9°, and no V. I and II gave 59% VI and no III in the absence of KOH. VI could be partially rearranged to III by heating its alc. solution while adding 0.5 mole KOH. Thus, the effect of KOH on the condensation could be explained by assuming a rearrangement of the 1st formed 3-substituted-5,5-diphenylglycocyamidine in the presence of KOH into the corresponding 2-(substituted-imino)-4,4-diphenylimidazolidin-5-one.
IT **17050-07-6**, 4-Imidazolidinone, 2-imino-3-(2-morpholinoethyl)-5,5-diphenyl-
(preparation of)
RN 17050-07-6 CAPLUS
CN 4-Imidazolidinone, 2-imino-3-(2-morpholinoethyl)-5,5-diphenyl- (6CI, 8CI) (CA INDEX NAME)





```
=> => d his

     (FILE 'HOME' ENTERED AT 15:36:48 ON 25 MAR 2004)

     FILE 'REGISTRY' ENTERED AT 15:36:56 ON 25 MAR 2004
L1                STRUCTURE UPLOADED
L2              8 S L1 SSS SAM
L3            215 S L1 SSS FUL
L4                STRUCTURE UPLOADED
L5              4 S L4 SSS SAM SUB=L3
L6             40 S L4 SSS FUL SUB=L3
L7                STRUCTURE UPLOADED
L8              2 S L7 SSS SAM SUB=L3
L9             46 S L7 SSS FUL SUB=L3
L10            86 S L6 OR L9
L11           129 S L3 NOT L10

     FILE 'CAPLUS' ENTERED AT 15:43:33 ON 25 MAR 2004
L12            31 S L11

     FILE 'CAOLD' ENTERED AT 15:44:14 ON 25 MAR 2004

=> s l11
L13            8 L11

=> d l13 1-8 bib,hitstr
```

L13 ANSWER 1 OF 8 CAOLD COPYRIGHT 2004 ACS on STN
AN CA64:8195a CAOLD
TI 1-phenyl-3-alkylimidazolin-2-ones
AU Luckenbaugh, Raymond W.
PA Du Pont de Nemours, E. I., & Co.
DT Patent

PATENT NO.	KIND	DATE
US 3216816		1965

Same as #2

IT **5322-80-5** **5323-11-5** **5323-12-6** **97594-89-3**

RN 5322-80-5 CAOLD
CN 2-Imidazoline, 2-amino-2'-undecyl-1,1'-ethylenedi-, hydrochloride (7CI, 8CI) (CA INDEX NAME)



● HCl

RN 5323-11-5 CAOLD
CN 2-Imidazoline, 2-amino-2'-undecyl-1,1'-ethylenedi- (7CI, 8CI) (CA INDEX NAME)



RN 5323-12-6 CAOLD
CN 2-Imidazoline, 2-amino-2'-heptyl-1,1'-ethylenedi- (7CI, 8CI) (CA INDEX NAME)



RN 97594-89-3 CAOLD
CN 2-Imidazoline, 2-amino-2'-heptyl-1,1'-ethylenedi-, hydrochloride (7CI) (CA INDEX NAME)



● x HCl

L13 ANSWER 2 OF 8 CAOLD COPYRIGHT 2004 ACS on STN
AN CA64:8194g CAOLD
TI diimidazolines
AU Siegele, Frederick H.
PA American Cyanamid Co.
DT Patent

PATENT NO.	KIND	DATE
US 3222376		1965

IT **5322-79-2 30790-27-3 30917-23-8**
102322-99-6 102323-00-2
RN 5322-79-2 CAOLD
CN 2-Imidazoline, 2-amino-2'-heptyl-1,1'-ethylenedi-, monohydrochloride (8CI) (CA INDEX NAME)



● HCl

RN 30790-27-3 CAOLD
CN 1H-Imidazol-2-amine, 1-[2-[2-(heptadecadienyl)-4,5-dihydro-1H-imidazol-1-yl]ethyl]-4,5-dihydro- (9CI) (CA INDEX NAME)

CM 1

CRN 47660-80-0
CMF C25 H49 N5



RN 30917-23-8 CAOLD
CN 1H-Imidazol-2-amine, 1-[2-[2-(heptadecadienyl)-4,5-dihydro-1H-imidazol-1-yl]ethyl]-4,5-dihydro-, monohydrochloride (9CI) (CA INDEX NAME)

CM 1

CRN 47660-80-0
CMF C25 H49 N5



RN 102322-99-6 CAOLD
CN 2-Imidazoline, 2-amino-2'-heptadecenyl-1,1'-ethylenedi- (7CI) (CA INDEX NAME)

CM 1

CRN 47660-80-0
CMF C25 H49 N5



RN 102323-00-2 CAOLD
CN 2-Imidazoline, 2-amino-2'-heptadecenyl-1,1'-ethylenedi-, hydrochloride (7CI) (CA INDEX NAME)

CM 1

CRN 47660-80-0
CMF C25 H49 N5



L13 ANSWER 3 OF 8 CAOLD COPYRIGHT 2004 ACS on STN
AN CA61:651h CAOLD
TI 1-phenethyl-2-iminoimidazolidines, a class of compds. with ganglion-regulating activity
AU Wollweber, Hartmund; Hiltmann, R.; Stoepel, K.; Kroneberg, G.
IT **94523-80-5 94882-14-1 94934-39-1 96197-87-4 96197-88-5 96197-90-9 96197-96-5 96433-97-5 96434-01-4 96651-72-8**
RN 94523-80-5 CAOLD
CN 1H-Imidazole-1-ethanol, 2-amino-4,5-dihydro-α-phenyl-, monohydrobromide (9CI) (CA INDEX NAME)





● HBr

RN 94882-14-1 CAOLD
CN Imidazolidine, 1-(p-chlorophenethyl)-2-imino-, hydrobromide (7CI) (CA INDEX NAME)



Same as before

● HBr

RN 94934-39-1 CAOLD
CN Imidazolidine, 1-(m-chlorophenethyl)-2-imino-, hydrobromide (7CI) (CA INDEX NAME)



● HBr

RN 96197-87-4 CAOLD
CN Imidazolidine, 2-imino-1-(o-methylphenethyl)-, hydrobromide (7CI) (CA INDEX NAME)



● HBr

RN 96197-88-5 CAOLD
CN Imidazolidine, 2-imino-1-(p-methylphenethyl)-, hydrobromide (7CI) (CA INDEX NAME)



● HBr

RN 96197-90-9 CAOLD
CN Imidazolidine, 2-imino-5-methyl-1-phenethyl-, hydrobromide (7CI) (CA INDEX NAME)



● HBr

RN 96197-96-5 CAOLD
CN Imidazolidine, 2-imino-1-(p-methoxyphenethyl)-, hydrobromide (7CI) (CA INDEX NAME)



● HBr

RN 96433-97-5 CAOLD
CN Imidazolidine, 2-imino-1-(m-methylphenethyl)-, hydrobromide (7CI) (CA INDEX NAME)



● HBr

RN 96434-01-4 CAOLD
CN Imidazolidine, 2-imino-1-(m-methoxyphenethyl)-, hydrobromide (7CI) (CA INDEX NAME)



● HBr

RN 96651-72-8 CAOLD
CN Imidazolidine, 2-imino-1-[3,4-(methylenedioxy)phenethyl]-, hydrobromide (7CI) (CA INDEX NAME)



● HBr

L13 ANSWER 4 OF 8 CAOLD COPYRIGHT 2004 ACS on STN
AN CA60:11246d CAOLD
TI pharmacology of a substance with ganglionstimulating activity
AU Kroneberg, Guenther; Stoepel, K.
IT **94523-85-0**
RN 94523-85-0 CAOLD
CN Imidazolidine, 2-imino-1-phenethyl-, sulfate (7CI) (CA INDEX NAME)

CM 1

CRN 72105-70-5
CMF C11 H15 N3



CM 2

CRN 7664-93-9
CMF H2 O4 S



L13 ANSWER 5 OF 8 CAOLD COPYRIGHT 2004 ACS on STN
AN CA57:15121h CAOLD
TI 1-cyclohexyl-5-(1-hydroxyalkyl)tetrazoles
AU Ugi, Ivar; Meyr, R.
DT Patent

PATENT NO.	KIND	DATE
DE 1131692		

IT **1692-98-4**
RN 1692-98-4 CAOLD
CN Imidazolidine, 2-imino-1-[m-(trifluoromethyl)phenethyl]-, hydrobromide (7CI, 8CI) (CA INDEX NAME)



● HBr

L13 ANSWER 6 OF 8 CAOLD COPYRIGHT 2004 ACS on STN
AN CA57:15121e CAOLD
TI 2-iminoimidazolidines
AU Wollweber, Hartmund; Hiltmann, R.; Kroneberg, G.; Stoepel, K.
PA Farbenfabriken Bayer A.-G.
DT Patent

PATENT NO.	KIND	DATE
BE 613662		

IT **94882-15-2 94934-39-1 96197-90-9**
96197-95-4 96197-96-5 96434-01-4
96651-72-8 98343-30-7
RN 94882-15-2 CAOLD
CN Imidazolidine, 1-(p-chlorophenethyl)-2-imino-, hydrochloride (7CI) (CA INDEX NAME)



● HCl

RN 94934-39-1 CAOLD
CN Imidazolidine, 1-(m-chlorophenethyl)-2-imino-, hydrobromide (7CI) (CA INDEX NAME)



● HBr

RN 96197-90-9 CAOLD
CN Imidazolidine, 2-imino-5-methyl-1-phenethyl-, hydrobromide (7CI) (CA INDEX NAME)



● HBr

RN 96197-95-4 CAOLD
CN Imidazolidine, 2-imino-1-(o-methoxyphenethyl)-, hydrobromide (7CI) (CA INDEX NAME)



● HBr

RN 96197-96-5 CAOLD
CN Imidazolidine, 2-imino-1-(p-methoxyphenethyl)-, hydrobromide (7CI) (CA INDEX NAME)



● HBr

RN 96434-01-4 CAOLD
CN Imidazolidine, 2-imino-1-(m-methoxyphenethyl)-, hydrobromide (7CI) (CA INDEX NAME)



● HBr

RN 96651-72-8 CAOLD
CN Imidazolidine, 2-imino-1-[3,4-(methylenedioxy)phenethyl]-, hydrobromide (7CI) (CA INDEX NAME)



● HBr

RN 98343-30-7 CAOLD
CN Imidazolidine, 1-(2,2-diphenylethyl)-2-imino-, hydrobromide (7CI) (CA INDEX NAME)



● HBr

L13 ANSWER 7 OF 8 CAOLD COPYRIGHT 2004 ACS on STN
AN CA54:16445i CAOLD
TI hydantoins, thiohydantoins, and glycocyamidines - (II) synthesis of 3-(dialkylaminoalkyl)-5,5-diphenylglycocyamidines
AU Lempert, Karoly; Breuer, J.; Lempert-Sreter, M.; Pataky, I.; Pfeifer, A. K.
IT **17050-07-6 111162-00-6**
RN 17050-07-6 CAOLD
CN 4-Imidazolidinone, 2-imino-3-(2-morpholinoethyl)-5,5-diphenyl- (6CI, 8CI) (CA INDEX NAME)



RN 111162-00-6 CAOLD
CN 4-Imidazolidinone, 2-imino-3-(2-morpholinoethyl)-5,5-diphenyl-, dihydrochloride (6CI) (CA INDEX NAME)



●2 HCl

L13 ANSWER 8 OF 8 CAOLD COPYRIGHT 2004 ACS on STN
AN CA54:14234h CAOLD
TI orientation in the condensation of benzil with monosubstituted guanidines
AU Lempert, Karoly; Lempert-Sreter, M.
IT **17050-07-6**
RN 17050-07-6 CAOLD
CN 4-Imidazolidinone, 2-imino-3-(2-morpholinoethyl)-5,5-diphenyl- (6CI, 8CI) (CA INDEX NAME)



```
=> log y
COST IN U.S. DOLLARS                          SINCE FILE      TOTAL
                                              ENTRY           SESSION
FULL ESTIMATED COST                           22.26           403.28

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)    SINCE FILE      TOTAL
                                              ENTRY           SESSION
CA SUBSCRIBER PRICE                           0.00            -21.48

STN INTERNATIONAL LOGOFF AT 15:44:38 ON 25 MAR 2004
```